1. State budgetary institution of high professional education «Moscow State University of Medicine and Dentistry named after A. I. Evdokimov» of the Ministry of Healthcare of the Russian Federation
2. Far-Eastern State Medical University
3. State Medical University named after I. I. Mechnikov of Russian Federation Ministry of Public Health
4. Scientifi c and clinical center of gastroenterology and Hepatology, Saint Petersburg state University
5. Multidisciplinary Medical Center of the Central Bank of the Russian Federation
6. Moscow Clinical and Research Center
7. Saratov State Medical University n. a. V. I. Razumovsky of Ministry of Healthcare of Russian Federation
8. Bashkir State Medical University
9. Pirogov Russian National Research Medical University
10. State Novosibirsk Regional Clinical Hospital
11. Orenburg State Medical University
12. Irkutsk State Academy of Postgraduate Education
13. Federal State Autonomous Educational Institution of Higher Education I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
14. Stavropol State Medical University
15. Krasnoyarsk State Medical University named after Prof. V. F. Voino-Yasenetsky
16. State educational institution of higher professional education «Chelyabinsk State Medical Academy of Federal Agency of Health Care and Social Development»
17. Voronezh State Medical University named after N. N. Burdenko
18. Kirov state medical university under the Ministry of Health of the Russian Federation
19. Federal State Educational Institution of Higher Education “The Volgograd State Medical University of Public Health Ministry of the Russian Federation” (VolgSMU)
20. Northern State Medical University
21. Federal State Budgetary Educational Institution of Higher Education «Rostov State Medical University» of the Ministry of Healthcare of the Russian Federation
22. Smolensk state medical university

Keywords:nonsteroidal anti-inflammatory drugs, antithrombotics, OTC drugs, gastroenteropathy, gastroenteroprotective agents, proton pump inhibitors, prostaglandin E2, H2-blockers of histamine receptors

Abstract:Guideliness for THE PREVENTION AND TREATMENT OF ESOPHAGO-GASTRO-ENTERO-COLOPATHY INDUCED BY NONSTEROIDAL ANTIINFLAMMATORY DRUGS “NSAID elaborated by the group of scentists and general practioners and adopted as National Recomendations at the XII National Congress of Therapists on November 23 and at the same time at the 18th congress of the Gastroenterological Scientific Society of Russia, 2017 in Moscow.

• References total 89 ⇓ :: .
  1. Conaghan P.G. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatology International. 2012;32(6):1491-1502. doi:10.1007/s00296-011-2263-6.
  2. Peura D.A. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors. Cleve Clin J Med. 2002;69Suppl 1: SI31-9.
  3. Koffeman A.R, Valkhoff V.E, Çelik S. et al. High-risk use of over-the-counter non-steroidal anti-inflammatory drugs: a population-based cross-sectional study. The British Journal of General Practice. 2014;64(621).
  4. Khan S, Mohammad A, O’Rourke K.P. An audit of the frequency of proton pump inhibitor (PPI) prescription in rheumatoid arthritis (RA) patients taking non-steroidal anti-inflammatory drugs (NSAIDs). Ir J MedSci. 2014 Dec;183(4):685-6.
  5. Takeuchi K. Pathogenesis of NSAID-induced gastric damage: Importance of cyclooxygenase inhibition and gastric hypermotility. World Journal of Gastroenterology: WJG. 2012; 18 (18): 2147-2160.
  6. Unified Clinical Protocol for Primary and Secondary Medical Care Peptic Ulcer of Stomach and Duodenum in Adults, Ukraine [September, 2014]
  7. Russian gastroenterological association clinical guidelines on diagnosis and treatment of NSAIDs-associated erosive and ulcerative lesions of the stomach and duodenum [Moscow, 2014]
  8. Abraham N.S, Hlatky M.A, Antman E.M, Bhatt D.L, Bjorkman D.J, Clark C.B, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Am J Gastroenterol. 2010 Dec;105(12):2533-49.
  9. Lanza F.L, Chan F.K, Quigley E.M; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104:728-738
  10. NICE Guidelines: Acute upper gastrointestinal bleeding in over 16s: management. Доступ по ссылке https://www.nice.org.uk/guidance/cg141 Последний доступ: 15 сентября 2016 г.
  11. Unified Clinical Protocol for Primary Medical Care Dyspepsia, Ukraine [August,2012]
  12. Rostom A, Moayyedi P, Hunt R. Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks [2008]. Aliment Pharmacol Ther. 2009 Mar 1;29(5):481-96.
  13. Allison M.C, Howatson A.G, Torrance C.J, et al. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med 1992; 327:749-54.
  14. Angel Lanas, Maarten Boers, Javier Nuevo. Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice. Ann Rheum Dis 2015; 74:675-681.
  15. García Rodríguez L.A, Barreales Tolosa L (2007) Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 132:498-506.
  16. Moskowitz R.W, Abramson S.B, Berenbaum F, Simon L.S, Hochberg M (2007) Coxibs and NSAIDs-is the air any clearer? Perspectives from the OARSI/International COX-2 Study Group Workshop 2007. OsteoarthrCartil 15:849-856.
  17. Makris, U., Kohler, M., &Fraenkel, L. (2010). Adverse Effects (AEs) of Topical NSAIDs in Older Adults with Osteoarthritis (OA): a Systematic Review of the Literature. TheJournalofRheumatology, 37(6), 1236-1243.
  18. Castellsague, J., Riera-Guardia, N., Calingaert, B., Varas-Lorenzo, C., Fourrier-Reglat, A., Nicotra, F., … Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project. (2012). Individual NSAIDs and Upper Gastrointestinal Complications: A Systematic Review and Meta-Analysis of Observational Studies (the SOS Project). Drug Safety, 35(12), 1127-1146.
  19. Garg A, Shoeb A, Moodahadu L.S, Sharma A, Gandhi A, and Akku S. Amtolmetin: A Reappraisal of NSAID with Gastroprotection. Arthritis. 2016; 2016: 7103705.
  20. Munro H.M, Walton S.R, Malviya S, Merkel S, Voepel-Lewis T, Loder R.T., Farley F.A. Low-dose ketorolac improves analgesia and reduces morphine requirements following posterior spinal fusion in adolescents. Can J Anaesth. 2002 May;49(5):461-6.
  21. Fries J.F, Williams C.A, Bloch D.A et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991; 91: 213-22.
  22. Gabriel S.E, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. AnnInternMed 1991; 115:787-96.
  23. Koch M, Dezi A, Tarquini M, Capurso L. Prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal mucosal injury: risk factors for serious complications. DigLiverDis. 2000 Mar;32(2):138-51.
  24. Cardile S, Martinelli M, Barabino A, Gandullia P, Oliva S, Nardo G et al. Italian survey on non-steroidal anti-inflammatory drugs and gastrointestinal bleeding in children. World J Gastroenterol. 2016 Feb 7; 22(5): 1877-1883.
  25. Derry S, Loke Y.K. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000 Nov 11;321(7270):1183-7
  26. Iijima K, Koike T, Ara N, Nakagawa K, Kondo Y, Uno K, Hatta W, Asano N, Imatani A, Shimosegawa T. Identification of a high-risk group for low-dose aspirin-induced gastropathy by measuring serum pepsinogen in H. pylori-infected subjects. J Gastroenterol. 2015 Mar;50(3):305-12
  27. Yeomans N.D, Lanas A.I, Talley N.J, Thomson A.B, Daneshjoo R, Eriksson B, Appelman-Eszczuk S, Långström G, Naesdal J, Serrano P, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment PharmacolTher. 2005; 22:795-801.
  28. Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open 2014; 4: e004587.
  29. Chang H.Y, Zhou M, Tang W, Alexander G.C, Singh S. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ. 2015 Apr 24;350: h1585.
  30. Mort J.R, Aparasu R.R, Baer R.K. Interaction between selective serotonin reuptake inhibitors and nonsteroidal antiinflammatory drugs: review of the literature. Pharmacotherapy. 2006 Sep;26(9):1307-13.
  31. Vonkeman H.E, deLeest H, van de Laar M, et al. Assessment of Helicobacter pylori eradication in patients on NSAID treatment. BMC Gastroenterology. 2012; 12:133.
  32. Kono Y, Okada H, Takenaka R, et al. Does Helicobacter pylori Exacerbate Gastric Mucosal Injury in Users of Nonsteroidal Anti-Inflammatory Drugs? A Multicenter, Retrospective, Case-Control Study. Gut and Liver. 2016;10(1):69-75.
  33. Sokic-Milutinovic A, Krstic M, Rozer-Smolovic B, Alempijevic T. Role of Helicobacter pylori infection in gastroduodenal damage in patients starting NSAID therapy: 4 Months follow-up study. DigDisSci. 2010 Oct;55(10):2887-92.
  34. Den Hollander W.J, Kuipers E.J. Current pharmacotherapy options for gastritis. Expert Opin Pharmacother. 2012 Dec;13(18): 2625-3.
  35. Warlé-van Herwaarden M.F, Koffeman A.R, Valkhoff V.E, ‘t Jong G.W, Kramers C, Sturkenboom M.C, De Smet P.A. Time-trends in the prescribing of gastroprotective agents to primary care patients initiating low-dose aspirin or non-steroidal anti-inflammatory drugs: a population-based cohort study. Br J Clin Pharmacol. 2015 Sep;80(3):589-98.
  36. Sebaldt R.J, Petrie A, Goldsmith C.H, Marentette M.A. Appropriateness of NSAID and Coxib prescribing for patients with osteoarthritis by primary care physicians in Ontario: results from the CANOAR study. Am J ManagCare. 2004 Nov;10(11 Pt 1):742-50.
  37. Ray W.A, Stein C.M, Byrd V, Shorr R, Pichert J.W, Gideon P et al; Educational program for physicians to reduce use of non-steroidal anti-inflammatory drugs among community-dwelling elderly persons: a randomized controlled trial. MedCare. 2001 May;39(5):425-35.
  38. Sung-Hun Lee, Chang-Dong Han, Ick-Hwan Yang, and Chul-Won Ha. Prescription Pattern of NSAIDs and the Prevalence of NSAID-induced Gastrointestinal Risk Factors of Orthopaedic Patients in Clinical Practice in Korea. J KoreanMedSci. 2011 Apr; 26(4): 561-567.
  39. Барановский А. Ю. Диагностика, профилактика и лечение НПВП-индуцированной колонопатии. Эксп. и клин.гастроэнтерология. 2017:146(10); стр.4-14
  40. Scarpignato C, Hunt R.H. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. GastroenterolClinNorthAm. 2010 Sep;39(3):433-64
  41. Lanas A, Benito P, Alonso J, Hernández-Cruz B, Barón-Esquivias G, Perez-Aísa Á et al. Spanish Society of Rhematology; Spanish Association of Gastroenterology; Spanish Society of Cardiology. Safe prescription recommendations for non-steroidal anti-inflammatory drugs: consensus document ellaborated by nominated experts of three scientific associations (SER-SEC-AEG). ReumatolClin. 2014 Mar-Apr;10(2):68-84
  42. Sostres C, Gargallo C.J, Arroyo M.T, Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2010 Apr;24(2):121-32.
  43. Natalie Schellack. An overview of gastropathy induced by nonsteroidal anti-inflammatory drugs. S AfrPharm J. 2012 Vol. 79 No 4.
  44. Sugano K, Choi M.G, Lin J.T, Goto S, Okada Y, Kinoshita Y, Miwa H, Chiang C.E, Chiba T, Hori M, Fukushima Y, Kim H.S, Chang C.Y, Date M; LAVENDER Study Group. Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study. Gut. 2014 Jul;63(7):1061-8.
  45. Scheiman JM, Lanas A, Veldhuyzen van Zanten S, Baldycheva I, Svedberg LE, Nagy P. Effect of esomeprazole on gastroduodenal erosions in patients at increased gastrointestinal risk treated with low-dose acetylsalicylic acid: a post-hoc analysis of the OBERON trial. Int J Cardiol. 2015 Mar 1; 182:500-2.
  46. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002; 4: CD002296.
  47. Hooper L, Brown T.J, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ. 2004 Oct 23;329(7472):948.
  48. Taha A.S, Hudson N, Hawkey C.J, Swannell A.J, Trye P.N, Cottrell J, Mann S.G, Simon T.J, Sturrock R.D, Russell R.I: Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med. 1996, 334: 1435-1439.
  49. Vaduganathan M, Bhatt D L, Cryer B L, Liu Y, Hsieh W H, Doros G, Cohen M, Lanas A, Schnitzer T J, Shook T L, Lapuerta P, Goldsmith M A, Laine L, Cannon C P; Исследователи COGENT. Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. J Am Coll Cardiol. 2016 Apr 12;67(14):1661-71.
  50. GI Leontiadis, A Sreedharan, S Dorward, P Barton, B Delaney, CW Howden, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. NIHR Health Technology Assessment programme: Executive Summaries.
  51. Mo C, Sun G, Lu M-L, et al. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. World Journal of Gastroenterology: WJG. 2015; 21(17): 5382-5392.
  52. Scheiman J.M, Behier E.M, Loeffler K.M, et al. Omeprazole ameliorates aspirin-induced gastroduodenal injury. Dig Dis Sci 1994; 39:97-103.
  53. Hawkey C.J, Karrasch J.A, Szczepañski L, Walker D.G, Barkun A, Swannell A.J, Yeomans N.D. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998 Mar 12;338(11):727-34.
  54. Graham D.Y, Agrawal N.M, Campbell D.R et al. Ulcer prevention in long-term users of nonsteroidal anti-in ammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs. lansoprazole. ArchIntern Med 2002; 162: 160-75.
  55. Park S.H, Cho C.S, Lee O.Y, Jun J.B, Lin S.R, Zhou L.Y, et al. Comparison of Prevention of NSAID-Induces Gastrointestinal Complications by Rebamipide and Misoprostol: A randomised, multicenter, сontrolled trial - STORM STUDY. J ClinBiochemNutr. 2007 Mar;40(2):148-55. doi: 10.3164/jcbn.40.148.
  56. Л. Б. Лазебник, В. Н. Дроздов, В. А. Ким. Эффективность фамотидина в профилактике НПВП-гастропатий. Результаты Российского многоцентрового исследования ЗАСЛОН-1 (ЗащитаСЛизистой Оболочки желудка от Нестероидных противовоспалительных препаратов), Эксп. и клин.гастроэнт., 2009, 2, 3-9
  57. Vakil N, Fennerty M.B. Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. AlimentPharmacolTher. 2003 Sep 15;18(6):559-68
  58. S. Agewall, M. Cattaneo J. P.Collet et al. Expert position paper on the use of proton pomp inhibitors in patients with cardiovascular disease and antitrombotic therapy. European Heart J., 2013, (34); 1708-1715.
  59. Qiang Niu, Zhongsu Wang, Yong Zhang, и др. Мета-анализ: комбинированное применение клопидогреля и ингибиторов протонной помпы сопровождается увеличением частоты тяжелых нежелательных сердечно-сосудистых явлений при ишемической болезни сердца, Journal of Cardiovascular Pharmacology and Therapeutics, 1-11, © TheAuthor(s) 2016, Разрешение на перепечатку: sagepub.com/journals Permissions.nav DOI: 10.1177/1074248416663647 cpt.sagepub.com
  60. Howden C.W. Review article: immediate-release proton-pump inhibitor therapy - potential advantages Aliment PharmacolTher. 2005 Dec;22Suppl 3:25-30.
  61. Castell D. Review of immediate-release omeprazole for the treatment of gastric acid-related disorders. Expert OpinPharmacother. 2005 Nov;6(14):2501-10.
  62. Castell D, Bagin R, Goldlust B, Major J, Hepburn B. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. AlimentPharmacolTher. 2005 Jun 15;21(12):1467-74.
  63. Yeomans N, Wilson I, Långström G, Hawkey C, Naesdal J, Walan A, Wiklund I. Quality of life in chronic NSAID users: a comparison of the effect of omeprazole and misoprostol. Scand J Rheumatol. 2001;30(6):328-34.
  64. Yeomans N.D, Tulassay Z, Juhasz L et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. Acid Suppression Trial: Ranitidine vs. Omeprazole for NSAIDassociated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338: 719-26.
  65. Cullen D, Bardhan K.D, Eisner M, Kogut D.G, Peacock R.A, Thomson J.M, Hawkey C.J. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. AlimentPharmacolTher. 1998 Feb;12(2):135-40.
  66. Лазебник Л.Б., Ткаченко Е. И., Абдулганиева Д. И. и др. «VI Национальные рекомендации по диагностике и лечению кислотозависимых и ассоциированных с Helicobacterpylori заболеваний (VI Московские соглашения)»; Экспер. и клин.гастроэнтерология, 2017;138(2):3-19. Lazebnik L. B., Tkachenko E. I., Abdulganieva D. I. et al. “VI Nacional’nye rekomendacii po diagnostike I lecheniyu kislotozavisimyh i associirovannyh s Helicobacter pylori zabolevaniy (VI Moskovskiye soglasheniya). Eksperimental’naya I klinicheskaya gastroenterologia. 2017; 138(2):3–19
  67. vanSoest E.M, Valkhoff V.E, Mazzaglia G, Schade R, Molokhia M, Goldstein J.L, Hernández-DíazS, Trifirò G, Dieleman J.P, Kuipers E.J, Sturkenboom M.C. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut. 2011 Dec;60(12):1650-9.
  68. Gigante A, Tagarro I. Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on ketoprofen/omeprazole. Clin Drug Investig. 2012 Apr 1;32(4):221-33.
  69. Weinblatt, Michael E., Genovese, Mark C., Kivitz, Alan J., Bello, Alfonso E., Grahn, Efficacy, Safety And Tolerability Of HZT-501, Including Users Of Low-Dose Aspirin, A Single-Tablet Combination Of Ibuprofen-Famotidine: Results Of Two Phase 3 Trials. Arthritis&Rheumatism, Volume 62, November 2010 AbstractSupplement.
  70. Sostek M.B, Fort J.G, Estborn L, Vikman K. Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers. CurrMedResOpin. 2011 Apr;27(4):847-54
  71. Fujimori S, Hanada R, Hayashida M, Sakurai T, Ikushima I, Sakamoto C. Celecoxib Monotherapy Maintained Small Intestinal Mucosa Better Compared With Loxoprofen Plus Lansoprazole Treatment: A Double-blind, Randomized, Controlled Trial. J Clin Gastroenterol. 2016 Mar;50(3):218-26.
  72. Gwen M.C Masclee, Vera E Valkhoff 1, Eva Mvan Soest, René Schade, Giampiero Mazzaglia, Mariam Molokhia, Gianluca Trifirò et al. Cyclo-oxygenase-2 inhibitors or nonselective NSAIDs plus gastroprotective agents: what to prescribe in daily clinical practice? Aliment Pharmacol Ther. 2013 July; 38(2): 178-189.
  73. B. P. M. Verhaegh, F. de Vries, A. A. M. Masclee, A. Keshavarzian, A. de Boer, P. C. Souverein, M. J. Pierik et al. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Aliment PharmacolTher 2016; 43: 1004-1013.
  74. Каратеев А.А., Насонов Е. Л., Ивашкин В. Т. и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике»; Ассоциация ревматологов России, Российское общество по изучению боли, Российская Гастроэнтерологическая Ассоциация, Российское кардиологическое общество, Ассоциация травматологов-ортопедов России, Ассоциация междисциплинарной медицины, Российская ассоциация паллиативной медицины. М. 2015. Karateyev A. A.. Nasonov E. L.. Ivashkin V. T. i dr. Klinicheskiye rekomendatsii «Ratsionalnoye primeneniye nesteroidnykh protivovospalitelnykh preparatov (NPVP) v klinicheskoy praktike»; Assotsiatsiya revmatologov Rossii. Rossiyskoye obshchestvo po izucheniyu boli. Rossiyskaya Gastroenterologicheskaya Assotsiatsiya. Rossiyskoye kardiologicheskoye obshchestvo. Assotsiatsiya travmatologov-ortopedov Rossii. Assotsiatsiya mezhdistsiplinarnoy meditsiny. Rossiyskaya assotsiatsiya palliativnoy meditsiny. M.. 2015
  75. Wiviott S D, Braunwald E, McCabe C H, Montalescot G, Ruzyllo W, et al, TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.
  76. Becker R.C, Bassand J.P, Budaj A, Wojdyla D.M, James S.K, Cornel J.H, French J, Held C, Horrow J, Husted S, Lopez-Sendon J, Lassila R, Mahaffey K.W, Storey R.F, Harrington R.A, Wallentin L. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2011;32:2933-2944.
  77. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS European Heart Journal (2016) 37, 2893-2962.
  78. Abraham N S, Noseworthy P A, Yao X, Sangaralingham L R, Shah N D. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study. Gastroenterology. 2017 Apr;152(5):1014-1022.
  79. Miller C S, Dorreen A, Martel M, Huynh T, Barkun A N. Risk of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017 Nov;15(11):1674-1683.
  80. Valgimigli M, Bueno H, Byrne R A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS European Heart Journal (2018) 39, 213-254.
  81. Bhatt D L, Cryer B L, Contant C F, Cohen M, Lanas A, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-1917.
  82. Hunt R, Lazebnik L.B, Marakhouski Yu.C, Manuc M, Ramesh G.N, et al. International Consensus on Guiding Recommendations for Management of Patients with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Induced Gastropathy - ICON-G. Euroasian Journal of Hepato-Gastroenterology. 2018; (JPJ356130218JHG) In-print.
  83. Parambir S Dulai, Siddharth Singh, Evelyn Marquez, Rohan Khera, Larry J Prokop, Paul J Limburg, Samir Gupta, Mohammad Hassan Murad. Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. BMJ, 2016; i6188 DOI: 10.1136/bmj.i6188
  84. Final Recommendation Statement: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication. U. S. Preventive Services Task Force. September 2017. https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/aspirin-to-prevent-cardiovascular-disease-and-cancer
  85. Л. И. Бурячковская, Н. В. Ломакин, А. Б. Сумароков, Е. А. Широков. Алгоритмы и шкалы риска тромбоза и кровотечения в кардиологии и неврологии. Практическое пособие. Рекомендации Национального научного общества воспаления, Российского научного медицинского общества терапевтов, Российского научного общества специалистов по рентгенэндоваскулярной диагностике и лечению. Справочное пособие для врачей общей практики, кардиологов, неврологов. М., 2018 L. I. Buryachkovskaya, N. V. Lomakin, A. B. Sumarokov, E. A. Shirokov, Algoritmy i shkaly riska tromboza i krovotecheniya v kardiologii i nevrologii. Prakticheskoye posobiye. Rekomendatsii Natsionalnogo nauchnogo obshchestva vospaleniya. Rossiyskogo nauchnogo meditsinskogo obshchestva terapevtov. Rossiyskogo nauchnogo obshchestva spetsialistov po rentgenendovaskulyarnoy diagnostike i lecheniyu. Spravochnoye posobiye dlya vrachey obshchey praktiki. kardiologov. nevrologov. M.. 2018
  86. H. Decousus, V. F. Tapson, J. F. Bergmann et al. IMPROVE Investigators. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators //Chest. - 2011. - Vol.139, N1. - P. 69-79
  87. Y. Falck-Ytter, C. W. Francis, N. A. Johanson et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest. - 2012. - Vol.141, Suppl.2. - Р.e278S-e325S
  88. M. Gould, D. A. Garcia, S. M. Wren et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest. - 2012. - Vol.141, Suppl.2. - P.e227S-e277S
  89. Пающик С. А. Профилактика внутрибольничных венозных тромбоэмболических осложнений с использованием информационных технологий. Дисс. к. м.н., М, 146 с Payushchik S. A. Profilaktika vnutribolnichnykh venoznykh tromboembolicheskikh oslozhneniy s ispolzovaniyem informatsionnykh tekhnologiy. Diss. k. m.n. M. 146 s.

Full text is published :
RECOMMENDATIONS FOR THE PREVENTION AND TREATMENT OF ESOPHAGO-GASTRO-ENTERO-COLOPATHY INDUCED BY NONSTEROIDAL ANTIINFLAMMATORY DRUGS “NSAID”. Experimental and Clinical Gastroenterology Journal. 2018;151(03):04-18
Read & Download full text

1. Moscow State University of Medicine and Dentistry named after A. I. Evdokimov
2. Multidisciplinary Medical Center of the Central Bank of the Russian Federation

Keywords:comorbid pathology, non-steroidal anti-inflammatory drugs, antithrombotic drugs, “Moscow classification”, risk of bleeding recurrence, risk of thromboembolic complications, multifocal lesions of the mucosa of the digestive tract

Abstract:In order to develop an algorithm for managing patients receiving NSAIDs and anti-thrombotic therapy, as well as classification of lesions of the mucosa of the digestive tract, against the background of the treatment, we used the experience of foreign colleagues and information resources: PubMed, Cochrane Library, MDConsult, DynaMed, Google Scholar, TRIP Database, which today is the most comprehensive in terms of coverage by the public meta-search system, which has an advanced document sorting system, existing normative documents, as well as own experience. The algorythm for management of patients cured with NSAIDs or АТА included assessment of the patient’s condition before the start of treatment, dynamic monitoring of complications based on clinical and laboratory data, endoscopic diagnostic data, and a decision support system in the form of the “Russian classification” of esophagogastroduodenoenterocolatopathy. The developed “Moscow classification” of multifocal lesions of the mucosa of the digestive tract with nonsteroidal anti-inflammatory and antithrombotic agents is presented in the form of a cascade that includes a common scale, an expanded (specifying) scale, and a stratification of the risks of recurrence of bleeding and thromboembolic complications. The proposed “Moscow classification” of lesions of the mucosa of the digestive tract with non-steroidal anti-inflammatory drugs and drugs for lowering blood clotting (L. B. Lazebnik, G. V. Belova) is a testament to the medicine of “Three P” - personified, preventive and predictive, accounting for a significant number of gender, anamnesis, functional and clinical-laboratory indicators. The application of the Russian classification refers to the decision-support system for the tactics of conducting an extremely complex category of patients with severe comorbid pathology.

• References total 24 ⇓ :: .
  1. D’Onofrio G, Safdar B, Lichtman J.H, Strait K.M, Dreyer R.P, Geda M, Spertus J.A, Krumholz H.M. Sex differences in reperfusion in young patients with ST-segment-elevation myocardial infarction: results from the VIRGO study. Circulation. 2015;131:1324-1332. doi: 10.1161/CIRCULATIONAHA.114.012293
  2. Dreyer R.P, Wang Y, Strait K.M, Lorenze N.P, D’Onofrio G, Bueno H, Lichtman J.H, Spertus J.A, Krumholz H.M. Gender differences in the trajectory of recovery in health status among young patients with acute myocardial infarction: results from the variation in recovery: role of gender on outcomes of young AMI patients (VIRGO) study. Circulation. 2015;131:1971-1980. doi: 10.1161/CIRCULATIONAHA.114.014503
  3. Stefanini G.G, Baber U, Windecker S, Morice M.C, Sartori S, Leon M.B, Stone G.W, Serruys P.W, Wijns W, Weisz G, Camenzind E, Steg P.G, Smits PC, Kandzari D, Von Birgelen C, Galatius S, Jeger R.V, Kimura T, Mikhail G.W, Itchhaporia D, Mehta L, Ortega R, Kim H.S, Valgimigli M, Kastrati A, Chieffo A, Mehran R. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. Lancet. 2013;382:1879-1888. doi: 10.1016/S0140-6736(13)61782-1
  4. Kalyani R.R, Lazo M, Ouyang P, Turkbey E, Chevalier K, Brancati F, Becker D, Vaidya D. Sex differences in diabetes and risk of incident coronary artery disease in healthy young and middle-aged adults. Diabetes Care. 2014;37:830-838. doi: 10.2337/dc13-1755
  5. Leifheit-Limson E.C, D’Onofrio G, Daneshvar M, Geda M, Bueno H, Spertus J.A, Krumholz H.M, Lichtman J.H. Sex differences in cardiac risk factors, perceived risk, and health care provider discussion of risk and risk modification among young patients with acute myocardial infarction: The VIRGO Study. J Am Coll Cardiol. 2015;66:1949-1957. doi: 10.1016/j.jacc.2015.08.859
  6. Wilmont K.A, O’Flaherty M, Capewell S, Ford E.S, Vaccarino V. Coronary heart disease mortality declines in the United States from 1979 Through 2011: evidence for stagnation in young adults, especially women. Circulation. 2015;132:997-1002. doi: 10.1161/CIRCULATIONAHA.115.015293
  7. 1-Й Всероссийский Форум антикоагулянтной терапии (ФАКТ-2016): сборник тезисов докладов на конференции Язык: русский ISBN: 978-5-7396-0357-9, 2016, 64с, Первый Московский государственный медицинский университет им. И. М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (Москва) 1 VserossiiskyForum antocoagulintnoy terpii (FAKT-2016): sbornik tezisov I dokladov na konferencii yasik russkiy ISBN: 978–5–7396–0357–9, 2016,64s, Pervii Moskovskii medicinsky universitet im. I. M. Sehenova Ministerstva zdravooshranenia I socialnogo razvitiya (Moskva)
  8. Mosca L, Hammond G, Mochari-Greenber ger H, Towfighi A, Albert M.A; American Heart Association Cardiovascular Disease and Stroke in Women and Special Populations Committee of the Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on High Bloo. Fifteen-year trends in awareness of heart disease in women: results of a 2012 American Heart Association national survey. Circulation. 2013;127:1254-1263, e1. doi: 10.1161/CIR.0b013e318287cf2f
  9. Tamis-Holland J.E, Lu J, Korytkowski M, Magee M, Rogers W.J, Lopes N, Mighton L, Jacobs A.K; BARI 2D Study Group. Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: a report from the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation 2 Diabetes). J Am Coll Cardiol. 2013;61:1767-1776. doi: 10.1016/j.jacc.2013.01.062
  10. Dehmer G.J, Weaver D, Roe M.T, Milford-Beland S, Fitzgerald S, Hermann A, Messenger J, Moussa I, Garratt K, Rumsfeld J, Brindis RG. A contemporary view of diagnostic cardiac catheterization and percutaneous coronary intervention in the United States: a report from the CathPCI Registry of the National Cardiovascular Data Registry, 2010 through June 2011. J Am Coll Cardiol. 2012;60:2017-2031. doi: 10.1016/j.jacc.2012.08.966
  11. Koopman C, Vaartjes I, Heintjes E.M, Spiering W, van Dis I, Herings R.M, Bots M.L. Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998-2010. Eur Heart J. 2013;34:3198-3205. doi: 10.1093/eurheartj/eht368
  12. Ступин В. А., Баглаенко М. В., Канн В. И., Силуянов С. В., Тропинин Р. Ю., Ардабацкий Л. Р., Соколов Р. С., Мартиросов А. В. Структура летальности при язвенных гастродуоденальных кровотечениях. // Хирургия им. Н. И. Пирогова. - 2013. -No5. - С. 31-35/ Stupin V. A., Baglaenko M. V., Kann V. I., Siluyanov S. V., Tropinin R. U., Ardabatskii L. R., Sokolov R. S., Martirosov A. V. Struktura lrtalnosti ghbyazvennish gastroduodenalnish krovotecheniyash.//Chirurgiya im.N.I.Pirogova.-2013.-N5.-S.31–35/.
  13. Иванова Е. В. Возможности современных методов энтероскопии в диагностике и лечении заболеваний тонкой кишки / Е. В. Иванова, Е. Д. Федоров, О. И. Юдин и др. // Экспериментальная и клиническая гастроэнтерология - 2010. - № 5 - С. 104-112 Ivanova E. V. Vozmognosti sovremennich metodov enteroscopii v diagnostike I lechenii zabolevanii tonkoi kishki/ Ivanova E. V., Fedorov E. D., Yudin O. I.i dr.// Eksperimentalnaya I klinicheskaya gsatroenterologiya-2010.-N5-S.104–112/
  14. Федоров Е, Д., Юдин О. И., Петров Д. Ю., Степнов, М.В., Иванова Е. В. Эффективность применения эндоскопической аргоноплазменной коагуляции в сравнении с биполярной диатермокоагуляцией при язвенных гастродуоденальных кровотечениях. //Российский журнал гастроэнтерологии, гепатологии, колопроктологии. - 2008. -No 6. - С. 33-37 Fedorov E. D., Yudin O. I., Petrov D. U., Stepnov M. V., Ivanova E. V. Effektivnost primeneniya endoscopicheskoya argonoplazmennoyi coaguliacii v sravnenii s bipoliarnoy diatermocoaguliaciey pri yazvennish gastroduodenalnish krovotecheniyash.// Rossiisky gurnal gastroenterologii, gepatologii, coloproctologii.-2008.-N6.-S.33–37.
  15. Иванова Е. В. Диагностическая и лечебная эндоскопия тонкой кишки с использованием однобаллонного энтероскопа / Е. Д. Федоров, Е. В. Иванова, М. Е. Тимофеев и др. // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. - 2008. - Прилож. № 32 - С. 185 Ivanova E. V. Diagnosticheskaya i lechebnaya endoscopiya tonkoyi kishki c ispolzovaniem odnoballonnogo enteroskopa/ E. D. Fedorov, E. V. Ivanova, M. E. Timofeev i dr.// Rossiisky gurnal gastroenterologii, gepatologii, coloproctologii.-2008.-Prilog. N32.-S.185.
  16. Fedorov E., Ivanova E., Timofeev M., Yudin O. The extent, limits and complications of diagnostic and therapeutic single-balloon enteroscopy in patients with small bowel abnormalities. Gut 2009, Vol.57, A233
  17. Guidelines for the management of atrial fibrillation, ESC, 2010 // European Heart Journal doi:10.1093/eurheartj/ehq278
  18. Haely J. S., Eikelboom J., Douketis J. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial // Circulation 2012;126:343-8
  19. Heart Disease and Stroke Statistics 2010 Update: A Report From the American Heart Association //Circulation 2010;121; e46-e215
  20. Hawkins N.M, Scholes S, Bajekal M, Love H, O’Flaherty M, Raine R, Capewell S. The UK National Health Service: delivering equitable treatment across the spectrum of coronary disease. Circ Cardiovasc Qual Outcomes. 2013;6:208-216. doi: 10.1161/CIRCOUTCOMES.111.000058
  21. Lip G.Y et al. Identifying patients at risk of stoke despite anticoagulation // Stroke 2010 in press
  22. Ko D.T, Wijeysundera H.C, Udell J.A, Vaccarino V, Austin P.C, Guo H, Velianou J.L, Lau K, Tu J.V. Traditional cardiovascular risk factors and the presence of obstructive coronary artery disease in men and women. Can J Cardiol. 2014;30:820-826. doi: 10.1016/j.cjca.2014.04.032.
  23. Rechenmacher S. J., Fang J. C. Bridging anticoagulation: primum non nocere // J Am Coll Cardiol, 2015, 66:1392-1403.
  24. Sherwood M. W. et al. Perioperative Management of Patients on the New Oral Anticoagulants// Circulation. 2014;129:1850-1859

Full text is published :
SYSTEMTIZING CLASSIFICATION OF MULTIFOCAL LESIONS OF THE MUCOSA OF THE DIGESTIVE TRACT BY NON-STEROIDAL ANTI-INFLAMMATORY AND ANTITROMBOTIC DRUGS (“MOSCOW CLASSIFICATION”). Experimental and Clinical Gastroenterology Journal. 2018;151(03):19-27
Read & Download full text

1. Tver State Medical University

Keywords:acute gastroduodenal erosions, chronic heart failure, clinical and endoscopic features, changes of gastric secretion, local microcirculatory disorders

Abstract:The study included 94 patients with CAD with CHF, which were divided into four groups, depending on the severity of CHF and the presence of acute erosions. The state of the gastroduodenal zone and terminal blood flow in its mucosa, the changes of gastric secretion were evaluated with methods, adapted to the severity of the patients’ condition and the peculiarities of the cardiac pathology. It was found that usually acute erosions in CHF I-IIa stage represented a few, small defects of tissues with localization in the body and (or) antral part of the stomach. Erosions in patients with CHF IIb-III stage were multiple, small or medium in size and occupied significant areas of the mucosa of the body and the antrum of the stomach and the bulb of the duodenum. Clinical presentation of acute erosions in CHF I-IIa stage was determined as unstable unsharply expressed epigastric pain and signs of gastric dyspepsia. In CHF IIb-III stage, stable dyspepsia dominated, while the symptoms of a mild pain syndrome receded into the background. The development of acute erosions in CHF was promoted by thrombohemorrhagic microcirculatory disorders in the gastroduodenal mucosa, the severity of which increased jointly to the severity of CHF. These changes were accompanied by abnormalities of gastric secretion, which were manifested by activation of the acid-peptic factor in combination with moderate suppression of the protective mucus components production in CHF I-IIa stage, and by increased pepsinogen and inhibition of protective mucus production, normal acid secretion - in CHF IIb-III stage. Acute gastroduodenal erosions in patients with CAD with CHF have a number of clinical, endoscopic and pathogenetic features, which are determined mainly by the severity of CHF.

• References total 12 ⇓ :: .
  1. Лазебник Л.Б., Звенигородская Л. А. Хроническая ишемическая болезнь органов пищеварения. - М.: Анахарсис, 2003. - 136 с Lazebnik L. B.. Zvenigorodskaya L. A. Khronicheskaya ishemicheskaya bolezn organov pishchevareniya. – M.: Anakharsis. 2003. – 136 s.
  2. Raja K. et al. An endoscopic study of upper-GI mucosal changes in patients with congestive heart failure // Gastrointest. Endosc. - 2004. - Vol. 60(6). - P. 887-893
  3. Ruiz-Laiglesia F.J. et al. Comorbidity in heart failure. Results of the Spanish RICA Registry // QJM. - 2014. - Vol. 107(12). - P. 989-994
  4. Русская Л. В. Желудочно-кишечные кровотечения у больных с хронической сердечной недостаточностью и сочетанной патологией // Рос. кардиол. журнал. - 2008. - № 5. - С. 31-36 Russkaya L. V. Zheludochno-kishechnyye krovotecheniya u bolnykh s khronicheskoy serdechnoy nedostatochnostyu i sochetannoy patologiyey // Ros. kardiol. zhurnal. – 2008. – № 5. – S. 31–36.
  5. Ярема И.В. и соавт. Острые эрозивно-язвенные гастродуоденальные поражения у больных ишемической болезнью сердца, цереброваскулярными болезнями и хроническими обструктивными болезнями легких // Хирург. - 2009. - № 12. - С. 5-13 Yarema I. V. i soavt. Ostryye erozivno-yazvennyye gastroduodenalnyye porazheniya u bolnykh ishemicheskoy boleznyu serdtsa. tserebrovaskulyarnymi boleznyami i khronicheskimi obstruktivnymi boleznyami legkikh // Khirurg. – 2009. – № 12. – S. 5–13.
  6. Shi H., Wu B. Y., Gong Y. A retrospective analysis of clinical characteristics and mortality of gastrointestinal bleeding in 414 elderly patients // Zhonghua Nei Ke Za Zhi. - 2011. - Vol. 50(8). - P. 642-645
  7. Бойко А. Н. Эффект тиотриазолина и состояние слизистой оболочки желудка при Helicobacter pylori-негативных гастропатиях у больных хронической сердечной недостаточностью // Международ. мед. журнал. - 2011. - № 4. - С. 25-30 Boyko A. N. Effekt tiotriazolina i sostoyaniye slizistoy obolochki zheludka pri Helicobacter pylori-negativnykh gastropatiyakh u bolnykh khronicheskoy serdechnoy nedostatochnostyu // Mezhdunarod. med. zhurnal. – 2011. – № 4. – S. 25–30.
  8. Звенигородская Л.А., Крюкова Н. Б., Макарьева Е. Д. Изменения тонкой кишки у больных с хронической недостаточностью кровообращения // Рос. гастроэнтерол. журнал. - 1998. - № 2. - С. 79 Zvenigorodskaya L. A.. Kryukova N. B.. Makaryeva E. D. Izmeneniya tonkoy kishki u bolnykh s khronicheskoy nedostatochnostyu krovoobrashcheniya // Ros. gastroenterol. zhurnal. – 1998. – № 2. – S. 79.
  9. Franceschi M. et al. Acid-related disorders in the elderly // Best Pract. Res. Clin. Gastroenterol. - 2009. - Vol. 23(6). - P. 839-848
  10. Mc Gee M.F., Rosen M. J., Ponsky J. L. Management of Acute Gastrointestinal Hemorrhage // Advances in Surgery. - 2006. - Vol. 40. - P. 119-158
  11. Leontiadis G.I., Molloy-Bland M.P., Moayyedi P., Howden C. W. Effect of comorbidity on mortality in patients with peptic ulcer bleeding: systematic review and meta-analysis // Am. J. Gastroenterol. - 2013. - Vol. 108(3). - P. 331-345
  12. Sandek A. et al. Intestinal Blood Flow in Patients with Chronic Heart Failure: A Link with Bacterial Growth, Gastrointestinal Symptoms, and Cachexia // J. Am. Coll. Cardiol. - 2014. - Vol. 64 (11). - P. 1092-1102

Full text is published :
ACUTE GASTRODUODENAL EROSIONS IN PATIENTS WITH CORONARY ARTERY DISEASE AND CHRONIC HEART FAILURE: CLINICAL AND ENDOSCOPIC FEATURES AND THE ROLE OF MICROCIRCULATORY AND GASTRIC SECRETION DISORDERS IN THEIR DEVELOPMENT. Experimental and Clinical Gastroenterology Journal. 2018;151(03):28-33
Read & Download full text

1. Kirov State Medical University

Keywords:Helicobacter pylori, antibiotic sensitivity, eradication therapy, stable angina, gastroduodenal pathology

Abstract:The study was conducted in two stages. At the first stage, 46 patients with stable angina with a combination of H. pylori-associated gastroduodenal pathology were consistently included in the study. During the endoscopic examination by esophagogastroduodenoscopy, a gastro-biopsy specimen was sampled for microbiological examination. The sensitivity of the analyzed isolates of H. pylori strains to antimicrobial agents (in vitro) was determined by bacteriological testing. In the second stage, patients (n = 46) underwent eradication therapy against the background of basic therapy: in group I (n = 25), taking into account the antibiotic susceptibility of H. pylori, in group II (n = 21) without antibiotic sensitivity. After eradication in all patients (n = 46), the effectiveness of therapy was tested by ELISA (determination of H. pylori antigen in the stool). In the first stage, resistance of H. pylori strains to metronidazole was found in 45.7% of patients, and levofloxacin in 4.4% of patients. The drugs of the standard triple line eradication resistance of strains of bacteria has not been established. Moderate and high sensitivity of H. pylori isolates to clarithromycin was detected in 56.5% and 39.1% of patients, respectively. Moderate and high sensitivity to amoxicillin was established in 73.9% and 8.7% of patients. At the second stage of the study, it was found that the effectiveness of eradication was 86.9% overall, while in the I group - 96%, in the II group - 76.2%. In 45.7% of patients with stable angina with concomitant gastroduodenal pathology, the resistance of H. pylori strains to metronidazole was revealed. The use of a bacteriological method for determining the sensitivity of H. pylori to antibiotics, makes it possible to improve the effectiveness of eradication therapy.

• References total 16 ⇓ :: .
  1. Приходько М.Н., Андреев К. В., Симонова Ж. Г. Оценка клинико-функциональных параметров у больных стабильной стенокардией с сопутствующей гастродуоденальной патологией // Вятский медицинский журнал. - 2016. - № 2. - С. 23-26 Prikhodko M. N.. Andreyev K. V.. Simonova Zh. G. Otsenka kliniko-funktsionalnykh parametrov u bolnykh stabilnoy stenokardiyey s soputstvuyushchey gastroduodenalnoy patologiyey // Vyatskiy meditsinskiy zhurnal. – 2016. – № 2. – S. 23–26.
  2. Исаков В.И., Домарадский И. В. Хеликобактериоз // М., ИД Медпрактика, 2003. - 412 с Isakov V. I. Domaradskiy I. V. Khelikobakterioz // M.. ID Medpraktika. 2003. – 412 s.
  3. Ivashkin V. T., Lapina T. L., Sheptulin A. A., Trukhmanov A. S. i soavt. Prakticheskiye shagi po profilaktike raka zheludka v Rossiyskoy Federatsii: algoritm vedeniya patsiyentov s khronicheskim gelikobakternym gastritom (Materialy i rezolyutsiya soveta ekspertov 9 dekabrya 2013 g.) // Rossiyskiy zhurnal gastroenterologii. gepatologii. koloproktologii. – 2014. – № 2(24). – S. 102–104.
  4. Graham D. Y., Lee Y. C., Wu M. S. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence // Clinical Gastroenterology and Hepatology. - 2014. - Vol. 12. - Р. 177-186.
  5. Elitsur Y., Lawrence Z., Russmann H. et al. Primary clarithromycin resistance to Helicobacter pylori and therapy failure in children: the experience in West Virginia // Journal of Pediatric Gastroenterology and Nutrition. - 2006. - Vol. 42. - Р. 327-328.
  6. Koletzko S., Richy F., Bontems P. et al. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe // Gut. - 2006. - Vol. 55. - Р. 1711-1716.
  7. Кудрявцева Л. В., Исаков В. А., Иваников И. О. и др. Резистентность Helicobacter pylori к метронидазолу, кларитромицину и амоксициллину в Москве, Санкт-Петербурге и Абакане в 2001 г. // Педиатрия. - 2002. - № 2 (приложение). - С. 61-63. Kudryavtseva L. V.. Isakov V. A.. Ivanikov I. O. i dr. Rezistentnost Helicobacter pylori k metronidazolu. klaritromitsinu i amoksitsillinu v Moskve. Sankt-Peterburge i Abakane v 2001 g. // Pediatriya. – 2002. – № 2 (prilozheniye). – S. 61–63.
  8. Кудрявцева Л. В. Биологические свойства Helicobacter pylori // Альманах клинической медицины. - 2006. - № 14. - С. 39-46 Kudryavtseva L. V. Biologicheskiye svoystva Helicobacter pylori // Almanakh klinicheskoy meditsiny. – 2006. – № 14. – S. 39–46.
  9. Барышникова Н.В., Денисова Е. В., Корниенко Е. А. и др. Эпидемиологическое исследование резистентности Helicobacter pylori к кларитромицину у жителей Санкт-Петербурга с язвенной болезнью // Экспериментальная и клиническая гастроэнтерология. - 2009. - № 5. - С. 73-76 Baryshnikova N. V.. Denisova E. V.. Korniyenko E. A. i dr. Epidemiologicheskoye issledovaniye rezistentnosti Helicobacter pylori k klaritromitsinu u zhiteley Sankt-Peterburga s yazvennoy boleznyu // Eksperimental’naya i klinicheskaya gastroenterologiya. – 2009. – № 5. – S. 73–76.
  10. Симонова Ж.Г., Мартусевич А. К., Тарловская Е. И. Клинико-гемодинамическая характеристика эффективности эрадикационной терапии у больных с сочетанием ишемической болезни сердца и язвенной болезни // Архив внутренней медицины. - 2014. - № 5. - С. 71-75 Simonova Zh.G., Martusevich A. K., Tarlovskaya E. I. Kliniko-gemodinamicheskaya kharakteristika effektivnosti eradikatsionnoy terapii u bolnykh s sochetaniyem ishemicheskoy bolezni serdtsa i yazvennoy bolezni // Arkhiv vnutrenney meditsiny. – 2014. – № 5. – S. 71–75.
  11. Kowalski M. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty // J. Physiol. Pharmacol. - 2001. - Vol. 52 (1). - P. 3-31
  12. Жебрун А. Б., Сварваль А. В., Ферман Р. С., Гончарова Л. Б. Методы лабораторной диагностики инфекции, обусловленной Helicobacter pylori // СПб, 2014. - 60 с Zhebrun A. B., Svarval A. V., Ferman R. S., Goncharova L. B. Metody laboratornoy diagnostiki infektsii. obuslovlennoy Helicobacter pylori // SPb. 2014. – 60 s.
  13. EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. 2013; Version 3.1. Available from: URL: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Consultation/EUCAST_clinical_breakpoints_for_Helicobacter_pylori.pdf
  14. Glupczynski Y., Megraud F., Lopez-Brea M., Andersen L. European Multicentre Survey of in Vitro Antimicrobial Resistance in Helicobacter pylori // European Journal of Clinical Microbiology and Infectious Diseases. - 2001. - Vol. 20. - Р. 820-823
  15. Симаненков В.И., Захарова Н. В., Жебрун А. Б., Сварваль А. В., Савилова И. В., Ферман Р. С. Резистентность Helicobacter pylori к антимикробным препаратам по результатам бактериологического тестирования // Лечащий врач. - 2015. - № 4. - С. 91-96 Simanenkov V. I., Zakharova N. V., Zhebrun A. B., Svarval A. V., Savilova I. V., Ferman R. S. Rezistentnost Helicobacter pylori k antimikrobnym preparatam po rezultatam bakteriologicheskogo testirovaniya // Lechashchiy vrach. – 2015. – № 4. – S. 91–96.
  16. Симонова Ж. Г., Мартусевич А. К., Тарловская Е. И. Анализ клинической эффективности эрадикационной терапии у больных ишемической болезнью сердца, ассоциированной с патологией гастродуоденальной зоны // Терапевтический архив. - 2017. - № 8. - С. 37-43 Simonova Zh. G., Martusevich A. K., Tarlovskaya E. I. Analiz klinicheskoy effektivnosti eradikatsionnoy terapii u bolnykh ishemicheskoy boleznyu serdtsa. assotsiirovannoy s patologiyey gastroduodenalnoy zony // Terapevticheskiy arkhiv. – 2017. – № 8. – S. 37–43.

Full text is published :
ASSESSMENT OF THE ANTIBIOTIC SUSCEPTIBILITY OF HELICOBACTER PYLORI IN PATIENTS WITH STABLE ANGINA WITH CONCOMITANT GASTRODUODENAL PATHOLOGY. Experimental and Clinical Gastroenterology Journal. 2018;151(03):34-40
Read & Download full text

1. Tver state medical university, department of faculty therapy

Abstract:Taking into account the action of endogenous and exogenous risk factors, to discuss mechanisms for regulating the morphofunctional state of the esophagus and the pathogenesis of HE at the cellular, intercellular, organ and systemic levels. The work is based on the analysis of literature data and the results of long-term studies of the author and employees of the Department of faculty therapy, conducted in 689 patients with clinical and morphological manifestations of HE. 124 of them were treated for GERD with reflux esophagitis (re) associated with chronic gastritis (CG), 129 for GERD and re due to biliary pathology, 181 for exacerbation of CG, 223 for recurrence of peptic ulcer disease (NAF) and 32 for non-comorbidities. Among patients with GERD and re in Association with CG, there were 61 males and 63 females, aged 30-60 years, and with GERD and re in biliary pathology, 42 males and 87 females in 86% of cases. Pathogenesis of the disease in the detection of risk factors associated with the violation of the regulatory systems of the body and interaction at the cellular, intercellular, organ, organ and systemic levels, leading to a decrease in multi-level protection mechanisms and the development of morphofunctional changes in the esophagus.

• References total 23 ⇓ :: .
  1. Pimanov S. I. Ezofagit, gastrit, yazvennaya bolezn: rukovodstvo dlya vrachei. M., 2000. - S. 78-134.
  2. Maev I. V. Gastroezofagealnaya refyuksnaya bolezn - bolezn HHI veka. // Lechaschii vrach - 2004. - № 4. - S. 10-14.
  3. Osadchuk M. A., Osadchuk M. M. Kliniko-endoskopicheskie i morfofunkcionalnie pokazateli v ocenke razvitiya gastroezofagealnoi reflyuksnoi bolezni // Ross. jurn. Gastroenter., gepatol., koloproktol. 2005. - № 5. - S. 12.
  4. Lazebnik L. B., Scherbakov P. L. Gastroenterologiya. M., «MK», 2011. - S. 14-78.
  5. Ivashkin V. T., Maev I. V., Truhmanov A. S. Pischevod Barretta. M., «Shiko», 2011. - T. 1. - 608 s.
  6. Vasilenko V. H., Grebenev A. L., Salman M. M. Bolezni pischevoda. M., «Medicina», 1971. - 407 s.
  7. Grigorev P. Ya., Yakovenko E. P. Diagnostika i lechenie yazvennoi bolezni i aktivnogo helikobakterialnogo gastroduodenita. // Russk. med. jurnal. - 1996. - S. 51-55.
  8. Grigorev P. Ya., Yakovenko E. P. Profilaktika i lechenie boleznei organov pischevareniya. M., 2000. - 119 s.
  9. Vasilev Yu. V. Gastroezofagealnaya reflyuksnaya bolezn v stadii reflyuks-ezofagita: diagnostika i terapiya // Farmateka, 2004. - № 13. - S. 1-5.
  10. Cimmerman Ya.S., Cimmerman I. Ya. Klassifikacii gastroduodenalnih zabolevanii i klinicheskih sindromov. Perm, 2014. - 153 s.
  11. Chernin V. V., Sekareva E. V. Ezofagiti. V aspekte narushenii regulyatornih sistem. Tver; 2017. - 268 s.
  12. Bordin D. S., Lazebnik L. B., Masharova A. A. Gastroezofagealnaya reflyuksnaya bolezn u pojilih. / Gastroenterologiya (Bolezni vzroslih). M., 2011. - S. 58-78.
  13. Dzhulaj G. S., Sekareva E. V. Gastrojezofageal’naja refljuksnaja bolezn’ i soedinitel’no-tkannye displazii v aspekte premorbidnosti i komorbidnosti // Jeksperim. i klinich. gastrojenterol. - 2014. - Vyp. 102. - № 2. - S. 16-20.
  14. Machabeli M. S. Trombo-gemorragicheskij sindrom kak obshhepatologicheskaja zakonomernost’ adaptacionnogo haraktera // Laborat. delo. - 1969. - № 8. - S. 451-455.
  15. Maev I. V. Pishhevod Barretta. Gastrojenterologija. M., 2011. - S. 14-58.
  16. Truhmanov A. S. Gastrojezofageal’naja refljuksnaja bolezn’: klinika, diagnostika, lechenie./ Bolezni organov pishhevarenija, 2001. - № 3. - S. 19-24.
  17. Chernin V. V., Parfenov A. I., Bondarenko V. M. Rybal’chenko O.V., Chervinec V. M. Simbiontnoe pishhevarenie cheloveka. Fiziologija, klinika, diagnostika i lechenie ego narushenij. Tver’: «Triada»; 2013. 232 s.
  18. Ugolev A. M. Jevoljucija pishhevarenija i principy jevoljucii funkcij. L.: «Nauka»; 1985. 544 s.
  19. Chernin V. V. Kliniko-jeksperimental’nye aspekty patogeneza, sanogeneza i lechenija jazvennoj bolezni. Tver’; 1994. 255 s.
  20. Chernin V. V. Bolezni pishhevoda, zheludka i dvenadcatiperstnoj kishki. M.: «MIA»; 2010. 528 s.
  21. Korot’ko G. F. Fiziologija organov pishhevarenija. Krasnodar; 2009. 667 s.
  22. Chernin V. V. Jazvennaja bolezn’. Tver’; 2000. 287 s.
  23. Chernin V. V. Hronicheskij gastrit. Tver’: «Triada»; 2006. 302 s.

Full text is published :
ETIOLOGY, MECHANISMS OF REGULATION OF THE MORPHOFUNCTIONAL STATE OF THE ESOPHAGUS AND PATHOGENESIS OF CHRONIC ESOPHAITIS. Experimental and Clinical Gastroenterology Journal. 2018;151(03):41-46
Read & Download full text

1. Tver state medical university, department of faculty therapy

Keywords:gastroesophageal reflux disease, duodenogastroesophageal reflux, phenotypic and visceral signs of connective tissue dysplasia, developmental predictors

Abstract:In 129 patients with DGER-associated GERD, aged 18-76 years, the presence and severity of phenotypic and visceral signs CTD were recorded using the original screening kit, which detects them in adult patients. Dysplastic-dependent phenotype was diagnosed in 59 people (15 men and 44 women), absence of signs of CTD - in 70 (27 men and 43 women). Among the phenotypic signs of CTD in patients with GERD predominate musculocutaneous (47,9%), osteoarticular (27,5%) and cranial (18,5%). Among visceral symptoms dominated cardia insufficiency (57,6%), hiatal hernia (HH) (54,2%), the structure anomalies of gallbladder (39,0%). Regardless of the sex of patients, the severity of CTD was moderate. Chance of developing DGER-associated GERD, in patients with dysplastic-dependent phenotype was 3,7 times higher compared with individuals with no evidence of CTD in the presence of HH; 1,4-1,6 times - with cardia insufficiency, abnormal forms of gallbladder and their combination; 4,3 times - with combination of HH and an abnormal forms of gallbladder. In the adult population of patients with DGER-associated GERD in 45,7% of cases it occurs on the background of the high frequency of phenotypic and visceral manifestations of CTD. Visceral manifestations (HH, cardia insufficiency, abnormal forms of the gallbladder, and others) at high frequency of phenotypic signs appear predictors of GERD associated with DGER.

• References total 17 ⇓ :: .
  1. Lazebnik L. B., Tkachenko E. I., Abdulganiyeva D. I. i dr. Natsionalnyye rekomendatsii po diagnostike i lecheniyu kislotozavisimykh i assotsiirovannykh s Helicobacter pylori zabolevaniy (VI Moskovskiye soglasheniya). Eksperimental’naya i klinicheskaya gastroenterologiya. 2017. № 2 (138). – S. 3–21.
  2. Starostin B. D. Gastroezofagealnaya reflyuksnaya bolezn (chast I). Epidemiologiya. faktory riska. Gastroenterologiya Sankt-Peterburga. 2014. № 1–2. – S. 2–14.
  3. Bordin D. S., Kolbasnikov S. V., Kononova A. G. Gastroezofagealnaya reflyuksnaya bolezn: tipichnyye problemy terapii i puti ikh preodoleniya. Doktor.ru. 2016. № 1 (118). – S. 14–18.
  4. Eherer A. Management of gastroesophageal reflux dsease: lifestyle modification and alternative approaches. Dig. Dis. – 2014; 32 (1–2). – Р. 149–151.
  5. Mayev I. V., Gulenchenko Yu.S., Andreyev D. N. i dr. Duodenogastroezofagealnyy reflyuks: klinicheskoye znacheniye i podkhody k terapii. Consilium Medicum. 2014. № 8 (16). – S. 5–8.
  6. Samsonov A. A., Golubev N. N., Andreyev N. G. i dr. Podkhody k diagnostike i lecheniyu gastroezofagealnoy reflyuksnoy bolezni v sochetanii s duodenogastroezofagealnym reflyuksom. Farmateka. 2012. № 10. – S. 10–15.
  7. Takahashi Y., Amano Y., Yuki T. et al. Impact of the composition of gastric reflux bile acids on Barrett's oesophagus. Digestive and Liver Disease. – 2011. – № 43 (9). – 692–697.
  8. Shishko V. I., Petrulevich Yu. Ya. Gastroezofagealnaya reflyuksnaya bolezn: anatomo-fiziologicheskiye osobennosti pishchevoda. faktory riska i mekhanizmy razvitiya (obzor literatury. chast I). Zhurnal Grodnenskogo gosudarstvennogo meditsinskogo universiteta. 2015. № 1 (19). – S. 19–25.
  9. Cram M., De Caestecker J. Hiatus hernia and gastro-oesophageal reflux disease. Medicine. – 2011. – № 39 (3). – Р. 132–136.
  10. Herregods T.V., Bredenoord A. J., Smout A. J. Pathophysiology of gastroesоphageal reflux desiase: new understanding in a new era. Neurogasrtoenterol. Motil. – 2015. – № 27 (9). – Р. 1202–1213.
  11. Arsentyev V. G., Shabalov N. P. Displaziya soyedinitelnoy tkani u detey kak konstitutsionalnaya osnova poliorgannykh narusheniy: voprosy klassifikatsii. kriterii diagnostiki. Voprosy prakticheskoy pediatrii. 2011. № 6 (5). – S. 59–65.
  12. Yakovlev V. M., Nechayeva G. I. Sistemnyye displazii soyedinitelnoy tkani: aktualnost problemy v klinike vnutrennikh bolezney. Sibirskiy meditsinskiy zhurnal. 2011. № 3–2 (26). – S. 9–12.
  13. Apenchenko Yu.S., Basalayeva N. V., Kapustina L. V. i dr. Klinicheskiye i biokhimicheskiye priznaki displazii soyedinitelnoy tkani u detey s gastroezofagealnoy reflyuksnoy boleznyu. Vestnik Ivanovskoy meditsinskoy akademii. 2014. № 3 (19). – S. 17–19.
  14. Butorina N. V., Zaprudnov A. M., Vakhrushev Ya. M. i dr. Kliniko-patogeneticheskoye znacheniye narusheniya metabolizma kollagena u detey s gastroezofagealnoy reflyuksnoy boleznyu. Eksperimental’naya i klinicheskaya gastroenterologiya. 2013. № 1. – S. 20–24.
  15. Kadurina T. I., Gorbunova V. N. Displaziya soyedinitelnoy tkani. Rukovodstvo dlya vrachey. Sankt-Peterburg. 2009. – 704
  16. Tabolin V. A., Shabalov N. P. Spravochnik neonatologa. Leningrad. 1984. – 320 s.
  17. Kadurina T. I., Abakumova L. N. Algoritm diagnostiki displazii soyedinitelnoy tkani u detey. Pediatricheskiye aspekty displazii soyedinitelnoy tkani. Dostizheniya i perspektivy. Moskva-Tver-Sankt-Peterburg. 2010. – S. 32–40.

Full text is published :
PROGNOSTIC VALUE OF CONNECTIVE TISSUE DISPLASIA IN DUODENOGASTROESOPHAGEAL REFLUX-ASSOCIATED GASTROESOPHAGEAL REFLUX DISEASE. Experimental and Clinical Gastroenterology Journal. 2018;151(03):47-52
Read & Download full text

1. Ogarev Mordovia State University
2. Mordovia Republican clinical hospital

Keywords:tumor necrosis factor-α, gastritis, peptic ulcer disease, polyposis, gastric cancer, Helicobacter pylori

Abstract:The aim of the study was to determine the serum level of tumor necrosis factor-α (TNF-α) with diseases of the stomach in correlation with the morphological changes of the gastric mucosa (GM). Examined with the informed consent of the 204 patients with precancerous diseases of the stomach, 40 patients with gastric cancer, and 40 healthy volunteers. The amount of TNF-α in serum was determined by enzyme immunoassay. The serum level of TNF-α in patients with chronic gastritis, peptic ulcer, polyposis, gastric cancer significantly exceeded the values of healthy individuals, correlated with the stage of atrophy, the degree of inflammation, colonization of GM Helicobacter pylori, severity ulcerative process, stage of tumor growth. Conclusion. Determining the number of TNF-α in serum can be used for immuno-laboratory assessment of severity and prognosis of the pathological process in the GM.

• References total 18 ⇓ :: .
  1. Sosnina A. V., Mikhaylova E. S., Autenshlyus A. I. et al. Tsitokinprodutsiruyushchiy potentsial kletok krovi i tsitokiny syvorotki bolnykh khronicheskim atroficheskim gastritom // Med. immunol. – 2013. – T. 15. № 3. – S. 247–254
  2. Ageyeva E. S. Effekty tsitokinov v patogeneze Helicobacter pylori-assotsiirovannykh khronicheskogo gastrita i yazvennoy bolezni // Sib. med. zhurn. – 2014. – № 2. – S. 5–8
  3. Eshanu V. S. Tsitokiny i ikh biologicheskiye effekty pri nekotorykh boleznyakh pecheni // Klin. persp. gastroenterol.. gepatol. – 2004. – № 5. – S. 11–16.
  4. Ketlinskiy S. A., Simbirtsev A. S. Tsitokiny. – SPb.: Foliant. 2008.
  5. Yarilin A. A. Immunologiya. M.: GEOTAR-Media. 2010.
  6. Matveyeva L. V., Stenina M. A., Mosina L. M. Tsitokinovaya regulyatsiya ultserogeneza slizistoy obolochki gastroduodenalnoy zony // Med. immunol. – 2013. – T. 15. № 2. – S. 107–119.
  7. Freydlin I. S., Sheykin Yu. A. Endotelialnyye kletki v kachestve misheney i produtsentov tsitokinov // Med. immunol. – 2001. – T. 3. № 4. – S. 499–514.
  8. Ostanin A. A., Paltsev A. I., Lebedev A. G. i soavt. Kharakteristika apoptoza i funktsionalnoy aktivnosti limfotsitov u bolnykh yazvennoy boleznyu // Byull. SO RAMN. – 2004. – № 1 (111). – S. 129–134.
  9. Bäckhed F., Rokbi B., Torstensson E. et al. Gastric mucosal recognition of Helicobacter pylori is independent of Toll-like receptor 4 // J. Inf. Dis. – 2003. – Vol. 187, no. 5. – P. 829–836.
  10. Casazza J.P., Betts M. R., Price D. A. et al. Acquisition of direct antiviral effector functions by CMV-specific CD4+T lymphocytes with cellular maturation // J. Exp. Med. – 2006. – Vol. 203. – P. 2865–2877.
  11. Matveyeva L. V. Mekhanizmy induktsii kletochnoy tsitotoksichnosti pri vospalitelnom protsesse v slizistoy obolochke zheludka // Med. immunol. – 2017. – T. 19. № 6. – S. 673–682.
  12. Dudayeva N. G., Grechushnikov V. B., Bugayeva I. O. i soavt. Immunologicheskiye i morfologicheskiye aspekty diagnostiki infektsii Helicobacter pylori i virusov semeystva Herpesviridae // Saratov. nauch. med. zhurn. – 2010. – № 6. – S. 361–364.
  13. Sokolova G. N., Potapova V. B. Kliniko-patogeneticheskiye aspekty yazvennoy bolezni zheludka. – M.: Anakharsis. 2009.
  14. Yarilin D. A. Rol faktora nekroza opukholey v regulyatsii vospalitelnogo otveta monotsitov i makrofagov // Immunologiya. – 2014. – № 4. – S. 195–201.
  15. Ivashkiv L. B. Epigenetic regulation of macrophage polarization and function // Trends Immunol. – 2013. – Vol. 34. – P. 216–223.
  16. Szaflarska A., Szczepanik A., Siedlar M. et al. Preoperative Plasma Level of IL-10 but not of Proinflammatory Cytokines Is an Independent Prognostic Factor in Patients with Gastric Cancer // Anticancer Res. – 2009. – Vol. 29, no. 12. – Р. 5005–5012.
  17. Kurusin V. M., Matveyeva L. V. Gendernyye osobennosti izmeneniy mikrobioty zheludka pri zabolevaniyakh gastroduodenalnoy zony // Eksp. i klin. gastroenterol. – 2016. – № 126 (2). – S. 25–29.
  18. Shavlakadze N., Purtskhvanidze B., Chkhikvadze L., Kintsurashvili A. Interleykin-10 i faktor nekroza opukholi u patsiyentov c khronicheskim gastritom. indutsirovannym H. pylori // Allergol. i immunol. – 2012. – T. 13. № 3. – S. 243–246.

Full text is published :
CHANGES OF THE SERUM LEVELS OF TUMOR NECROSIS FACTOR-Α AT DISEASES GASTRIC. Experimental and Clinical Gastroenterology Journal. 2018;151(03):53-57
Read & Download full text

1. Tver state medical university, department of faculty therapy

Abstract:84 patients with recurrent peptic ulcer disease and simtomatic gastroduodenal ulcers associated with nonsteroidal anti-inflammatory drugs (NSAIDs) were examined. The first group consisted of patients with relapse of UX, the second - patients with SRS. Groups did not differ in age, sex and localization of ulcers. Each included 7 men, with an average age of 49.4±3.6 years, and 7 women aged 51.2±2.2 years. 9 examined ulcers were located in the stomach, 5 - in the duodenum. All patients of these two groups, except for complex therapy, including diet, protective regime, cytoprotectors, anti-secretory agents, according to indications, preparations of eradication HP-therapy of the I line, received bmkk nifedipine 0.01 three times during the course of treatment (2-4 weeks). To clarify the effectiveness of the use of nifedipine in the treatment of relapse of gastric ulcer and duodenal ulcer and gastric ulcer and duodenal ulcer, a third group was formed, including 56 patients (42 men and 14 women) with relapse of gastric ulcer and duodenal ulcer (12 patients with ulcers of the stomach, 44 - duodenum), the average age of 33.9±11.7 years, who received similar therapy to the two main groups only without nifedipine. A study of blood calcium found that gastroduodenal ulcers are accompanied by a significant (p<0.05) increase compared to healthy individuals (2.04±0.05 mmol/l) in all groups. In the study of regional microcirculation in biopsies WITH periulcerous zone all patients with recurrent of gastric ulcer and duodenal ulcer and SGDU identified violations, characterized by congestion and enlargement of the capillaries and venules, arterioles spasm, microthrombuses, edema and hemorrhage in the perivascular tissue. However, SRS and a more significant increase in blood calcium levels were accompanied by more pronounced vascular and intravascular disorders, and relapse of gastric ulcer and duodenal ulcer - perivascular changes in the final blood flow. Comparing the presented data with the results of our studies presented in previous works, we can assume that the SRS as well as the recurrence of gastric ulcer and duodenal ulcer occurs against the background of dysfunction of the calcium regulating system with an increase in blood calcium levels, which contributes to the formation of such mechanisms of ulcerogenesis as violation of regional microcirculation, activation of the acid-peptic factor and the development of hypermotor dyskinesia of the stomach. Symptomatic gastroduodenal ulcers, as well as the recurrence of peptic ulcer disease, are accompanied by an increase in blood calcium levels, reflecting the dysfunction of the calcium regulating system and contributing to the formation of the main mechanisms of ulcerogenesis. The inclusion in the complex therapy of symptomatic gastroduodenal ulcers associated with NSAIDs and recurrence of peptic ulcer of slow calcium channel blockers is pathogenetically justified and clinically effective.

• References total 24 ⇓ :: .
  1. Kalinin, A. V. Simptomaticheskie gastroduodenal’nye jazvy i ga-stroduodenal’nye jazvy pri jazvennoj bolezni / A. V. Kalinin // Ros. zhurn. gastrojenterol. gepatol. koloproktol. - 2004. - T. 14, № 3. - S. 22-32.
  2. Cimmerman, Ja.S. Gastroduodenal’nye jerozivno-jazvennye povre-zhdenija, inducirovannye priemom nesteroidnyh protivovospalitel’nyh preparatov / Ja.S. Cimmerman, I.Ja. Cimmerman // Klin. med. - 2008. - № 2. - S. 8-12.
  3. SHeptulin, A. A. Sovremennye vozmozhnosti lechenija i profilaktiki NPVP-inducirovannoj gastropatii / A.A. Sheptulin // Ros. zhurn. gastrojenterol., gepatol., koloproktol. - 2006. - № 1. - S. 15-18.
  4. Roth, S. H. Nonsteroidal antiinflammatory drug gastropathy: new avenues for safety / S. H. Roth // Clin.Interv.Aging. - 2011. - Vol.6. - P. 125-131.
  5. Karataev, A. V. NPVP-associirovannaja patologija ZHKT: real’noe sostojanie del v Rossii / A. V. Karataev, E. L. Nasonov // Rus. med. zhurn. - 2006. - № 15. - S. 1073-1078.
  6. Sergeeva, V. V. Vozmozhnye nezhelatel’nye lekarstvennye reakcii pri lechenii nesteroidnymi protivovospalitel’nymi preparatami. Osobennosti techenija i lechenija zabolevanij u zhitelej blokadnogo Leningrada, lic pozhilogo i starcheskogo vozrasta. Vypusk VII. Osobennosti boleznej oporno-dvigatel’nogo apparata i rasstrojstva obmena veshhestv u blokadnikov, ih potomkov i pozhilyh ljudej Sankt-Peterburga / V. V. Sergeeva, T. A. Bobyleva, L.R. Judinceva. SPb.: Izd-vo RGPU im. A. I. Gercena. - 2011. - 511 s.
  7. Citoprotektory v terapii zabolevanij zheludka. Optimal’nyj podhod k vyboru preparata / A.V. Jakovenko, P.Ja. Grigor’ev, Je.P. Jakovenko i dr. // J. Eksper. i klin, gastrojenterol. - 2006. - № 2. - S. 1-4.
  8. Silen, W. The prevention and management of stress ulcers / W. Silen // Hosp. Pract. - 1980. - V. 15. - P. 93-100.
  9. Ugolev, A.M. O. S. Gormony pishhevaritel’noj sistemy: Fiziologija, patologija, teorija funkcional’nyh blokov / A. M. Ugolev, O. S. Radbil’. - M.: Nauka. - 1995. - 238 s.
  10. Shekina, E. G. Mehanizmy dejstvija i perspektivy primenenija sovremennyh NPVS / E.G. Shekina //Provizor. - 2007. - № 11. - S.38-41
  11. Chernin, V. V. Kal’cijregulirujushhaja sistema i recidiv jazvennoj bolezni / V.V. Chernin, L. A. Fomina // Ter. arhiv. - 2016. - № 88 (2). - S. 10-15.
  12. Fomina, L. A. Kal’cievo-fosfornyj balans pri recidive jazvennoj bolezni / L. A. Fomina // J. Eksper. i klin. gastrojenterol. - 2011. - № 12. - S. 22-26.
  13. Fomina, L. A. Patogeneticheskie osnovy i jeffektivnost’ primenenija blokatorov medlennyh kal’cievyh kanalov v terapii recidiva jazvennoj bolezni, associirovannoj s arterial’noj gipertoniej / L. A. Fomina // Ter. arhiv. - 2017. - № 2. - S. 10-14.
  14. Ugolev, A. M. Estestvennye tehnologii biologicheskih sistem / A. M. Ugolev. L.: Nauka. - 1987. - 317 s.
  15. Ivashkin, V. T. Teorija funkcional’nyh blokov i problemy klinicheskoj mediciny / V. T. Ivashkin, G. A. Minasjan, A. M. Ugolev. - L.: Nauka. - 1990. - 303 s.
  16. Ca2+ signaling in porcine duodenal glands by muscarinic receptor activation / H. Teraoka, Y. Maruyama, K. Takehana et all. // Am. J. Physiol. Gastrointest. Liver Physiol. - 2001. - Vol. 280. - P. G729-G737/
  17. The stomach divalent ion-sensing receptor scar is a modulator of gastric acid secretion / J. P. Geibel, C. A. Wagner, R. Caroppo et all. // J. Biol. Chem. - 2001. - Vol. 276. - P. 39549-39552/
  18. Muller, M. J. Control of pepsinogen synthesis and secretion / M. J. Muller, J. Defize, R. H. Hunt // Gastroent. Clin. North. Amer. - 1990. - Vol. 19. - P. 27-40/
  19. Fomina, L. A. Znachenie kal’cijregulirujushhej sistemy v razvitii narushenij mikrocirkuljacii i gemostaza pri recidive jazvennoj bolezni / L. A. Fomina // Ter. arhiv. - 2014. - T. 86. - № 2. - S. 13-16.
  20. Fomina, L. A. Rol’ kal’cijregulirujushhej sistemy v patogeneze i sanogeneze jazvennoj bolezni i korrekcija ee sdvigov pri lechenii recidiva zabolevanija / L. A. Fomina // J. Eksper. i klin. gastrojenterol. - 2016. - № 10 (134). - S. 19-24.
  21. CHernin, V. V. Patogeneticheskie osnovy primenenija antagonistov kal’cija v lechenii recidiva jazvennoj bolezni / V.V. Chernin, L. A. Fomina // J. Eksper. i klin. gastrojenterol. - 2003. - № 4. - S. 41-48
  22. Koncentracija magnija i kal’cija v biologicheskih sredah i reparacija tkanej zheludochno-kishechnogo trakta u stressustojchivyh i stressneustojchivyh krys s jeksperimental’nymi jazvami zheludka do i posle primenenija magnijsoderzhashhej lekarstvennoj kompozicii / L. N. Rogova, N. V. Grigor’eva, V. V. Ermilov, V. N. Povetkina // Vestnik Volgogradskogo gosudarstvennogo medicinskogo universiteta. - 2013. - № 3. - S28-31
  23. Fomina, L. A. Znachenie funkcional’nogo sostojanija parashhi-tovidnyh zhelez v ul’cerogeneze / L. A. Fomina, G. V. Homullo // J. Eksper. i klin. gastrojenterol. - 2009. - № 4. - S. 17-20
  24. Chernin, V. V. Znachenie kal’cijregulirujushhej sistemy v patogeneze jeksperimental’noj jazvy u krolikov / V.V. Chernin, L. A. Fomina, G. V. Homullo //. Jeksper. i klin. gastrojenterol. - 2010. - № 11. - S. 63-66

Full text is published :
CALCIUM IMBALANCE IN THE PATHOGENESIS OF SYMPTOMATIC GASTRODUODENAL ULCERS ASSOCIATED WITH NONSTEROIDAL ANTIINFLAMMATORY DRUGS, AND EFFECTIVENESS OF BLOCKERS OF SLOW CALCIUM CHANNELS IN THEIR TREATMENT. Experimental and Clinical Gastroenterology Journal. 2018;151(03):58-63
Read & Download full text

1. Federal State Budgetary Educational Institution of Higher Education “Rostov State Medical University” of the Ministry of Healthcare of the Russian Federation

Keywords:total immunoglobulin E, IgE, violation of carbohydrate metabolism, blood groups, diabetes mellitus, specific immunoglobulin E, insulin

Abstract:The following are determined: total IgE; specific IgE; The level of glucose and the percentage of glycosylated hemoglobin (HbA1c) in the serum; insulin in different blood groups 0(I), A(II), B(III) (n = 110). At the expressed infringement of a carbohydrate exchange representatives 0 (I) and And (II) groups of a blood had indicators of the general IgE43,61±15,12 kIU/l and 86,2 ± 42,61 kIU/l accordingly, that on the average in 4 times lower than blood group B(III), whose total IgE in type 2 diabetes increased 2 times the upper limit of normal and was 209,65 ± 52,5 kIU/l. It is also shown that individuals with different blood groups and glucose levels have individual reactions of induction of IgE to insulin. In B(III) blood group with glucose below 4 mmol/l, the lowest induction of insulin was observed - 0,85±0,05 μE/ml, and the production of IgE to insulin increased 80 times, amounting to 113,0±56,0 kU/l. It can be assumed that the outbreak of total IgE in people with a border glucose level (6,2-7,8 mmol/l), glycosylated hemoglobin (5,9-6,9%) in O(I) and A(II) blood groups may be a predictor of the onset of diabetes mellitus, and also reflect the state of compensation mechanisms for impaired glucose tolerance, as demonstrated in the B(III) blood group, which has high levels of total IgE with marked glucose tolerance. All three groups of blood to increase the level of glucose and insulin in the blood, as well as with expressed type 2 diabetes, react with a decrease in the production of specific IgE to insulin.

• References total 15 ⇓ :: .
  1. Kolotyeva N. A., Shakhnovich E. A., Nefedova N. S. i soavt. Rol malykh molekul v realizatsii belok-belkovykh vzaimodeystviy // Aktualnyye problemy biokhimii i bionanotekhnologii: sbornik trudov II Mezhdunarodnoy internet-konferentsii. Kazan: izdatelstvo «Kazanskiy universitet». – 2011. – S.152–153.
  2. Vasilyev Yu. V., Belyayeva B. C. Patogeneticheskiye aspekty Helicobacter pylori // Eksperim. i klinich. gastroenterologiya. – 2006. – № 1. – S.28–36.
  3. Telesmanich N. R., Kolyakina A. V., Lomov Yu.M., Menshikova E. A. Mironova A. V. Kharakteristika adgezivnoy aktivnosti kholernykh vibrionov na eritrotsitakh mlekopitayushchikh dlya vybora dopolnitelnogo oriyentirovochnogo testa ikh epidemicheskoy znachimosti // Klinicheskaya laboratornaya diagnostika. – 2008. – T. 7. – C. 45–48.
  4. Telesmanich N. R., Lomov Yu. M. Lektiny kholernykh vibrionov kak osnovnyye faktory patogennosti i persistentsii (biotekhnologicheskiye aspekty ispolzovaniya) // Zhurnal mikrobiologii. epidemiologii i immunobiologii. – 2012. – № 2. – S.93–99
  5. Lai C.-Y., Lin S.-Y., Wu C.-K, Yen L.-T., Sytwu H.-K., Miaw S.-C. Tyrosine phosphorylation of c-Maf enhance the expression of IL-4 gene // Immunol. – 2012. – Vol. – 189 (4). – P. 1545–1550.
  6. Ospelnikova T. P., Lizogub N. V., Osipova G. L. Primeneniye induktorov interferona v kompleksnoy terapii bolnykh allergicheskimi zabolevaniyami // Meditsinskaya immunologiya. – 2009. – T.11. № 4–5. – S. 354–355.
  7. Klamt S., Vogel M., Hiemisch A., Prensel F., Zachariae S., Ceglarik U., Thiery I., Kiess W. “Association between IgE mediated allergiesand diabetes mellitus tupe 1 in children and adolescents” // Pediatric Diadetes. – 2015. – Vol. 16. – P. 493–503.
  8. Donath M.Y., Shoelson S. E. Type 2 diabetes as an inflanematory disease // Natur Rev. Immunol. – 2011 – Vol. 11 – P. 98–107.
  9. Telesmanich N. R., Konovalchik M. A., Mikashinovich Z. I. Analiz urovnya obshchego immunoglobulina E(IGE) v syvorotke krovi lyudey s razlichnymi tipami narusheniy uglevodnogo obmena i gruppami krovi 0(I). A(II). V(III) // Klinicheskaya laboratornaya diagnostika. – 2017. – T. 62. – № 8 – C. 476–481. DOI: 10.18821/0869–2084–2017–62–8–476–481.
  10. Gayduk I. M., Korostovtsev D. S., Shaporova N. L., Breykin D. V., Trusova O. V., Kamayeva I. A. Izmeneniye immunologicheskikh pokazateley pri provedenii sublingvalnoy allergen-spetsificheskoy immunoterapii u detey s pollinozom // Meditsinskaya immunologiya. – 2013. – T. 15. № 1. – S. 51–54. DOI:10.15789/1563–0625–2013–1–51–54
  11. Jabara H., Loh R., Ramesh N. et. al. Sequential switching from μ to ε via γ4 in human B cells stimulated with IL-4 and hydrocortisone // J. Immunol. – 1993 – Vol. 151 – P. 4528–4533.
  12. Kimata H., Fujimoto M. Growth hormone and insulin-like growth factor 1 induce IgE and IgG4 production by human B cells // J. Exp. Med. – 1994 – Vol. 180 – P. 727–732.
  13. Roep B. O. The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure // Diabetologia. – 2003. – Vol. 46, no. 3. – P. 305–321.
  14. Kologrivova I. V., Suslova T. E., Koshelskaya O. A., Vinnitskaya I. V., Trubacheva O. A. Vliyaniye glyukozy i insulina na sekretsiyu tsitokinov mononuklearami perifericheskoy krovi in vitro // Immunopatologiya i klinicheskaya immunologiya. – 2013. – T. 5. – S. 267–270.
  15. Zubatkina O. V., Dobrodeyeva L. K., Popov A. A. Znachimost urovnya leptina pri otsenke sostoyaniya adaptivnogo immuniteta // Ekologicheskaya fiziologiya. – 2015. – T. 12. C. 16–20.

Full text is published :
REAGIN SPECIFIC REACTION OF REPRESENTATIVES OF DIFFERENT BLOOD GROUPS AS A SYSTEM OF INDIVIDUAL TYPICAL DISEASE OF PANCREAS DISEASES WITH HYPOTHERMAL EXCHANGER DISTURBANCES. Experimental and Clinical Gastroenterology Journal. 2018;151(03):64-70
Read & Download full text

1. Krasnoyarsk State Medical University named after prof. V. F. Voyno-Jaseneckiy

Keywords:sharp necrotizing pancreatitis, parapancreatitis, pancreatonecrosis

Abstract:223 patients with acute necrotizing pancreatitis were examined. The conclusion about the nature of defeat was based on clinical, laboratory and instrumental data. Assessment of a condition of a pancreas was carried out on the basis of the KT-angiography with contrasting on 9 [7; 14] days from the beginning of a disease. Further conducted the dynamic research. Spread of parapancreatitis estimated according to classification of K. Ishikawa. Determined blood α-amylase level at receipt and α-amylases of the exudate received during a drainage of the acute liquid congestions (ALC), the level of the homocysteine, the level of C-reative protein. At patients the right type of injury of a pancreas - 67,71±3,13% of cases prevailed, the left type was observed in 13,45±2,28% of cases, and multiple damage - 18,83±2,62% of cases. At deep right type of a pancreatonecrosis in 62,91±3,93% of cases observed existence of the isolated functioning sites of a head of a pancreas which lost anatomic communication with a pancreatic channel. At the left type - 23,33±7,72% of cases. At a multiple necrosis - in 61,90±7,49% of cases. In the presence of the isolated site in all cases widespread parapancreatitis was created. ALC in the presence of the isolated site are formed in earlier terms - 19 [16; 21] days from the beginning of a disease also have high enzymatic activity of a α-amylase - 2540 [2130; 2620] piece/l. The right type of damage of a pancreas prevails. At deep defeat of an isthmus the isolated site of the functioning parenchyma of gland and internal pancreatic fistula is formed that is characteristic of the right type and multiple damage of a pancreas. At the left type of a pancreatonecrosis formation of the isolated site perhaps in rare instances of a deep necrosis of a body of gland. Existence of the isolated site of a parenchyma leads to formation of widespread parapancreatitis with early formation of ALC which are characterized by high enzymatic activity.

• References total 11 ⇓ :: .
  1. Pelts V. A. Sovremennoye sostoyaniye diagnostiki i khirurgicheskogo lecheniya ostrogo pankreatita. Sibirskiy meditsinskiy zhurnal. 2010; 4: 27–33.
  2. Freeman M. L. Werner J., van Santvoort H. C., Baron T. H., Besselink M. G., Windsor J. A., Horvath K. D., vanSonnenberg E., Bollen T. L., Vege S. S. Interventions for necrotizing pancreatitis: summary of a multidisciplinary consensus conference. Pancreas. 2012; 41: 1176–1194.
  3. Kokosis G., Perez A., Pappas T. N. Surgical management of necrotizing pancreatitis: an overview. World J Gastroenterol. 2014; 20(43): 16106–16112. DOI: 10.3748/wjg.v20.i43.16106.
  4. Vinnik Yu.S., Dunayevskaya S. S., Antyufriyeva D. A. Vozmozhnosti sovremennykh metodov vizualizatsii ostrogo tyazhelogo pankreatita. Novosti khirurgii. 2014; № 1(22): 58–62.
  5. Dellinger E.P., Forsmark C. E., Layer P., Levy P., Maravi-Poma E., Petrov M. S., Shimosegawa T., Siriwardena A. K., Uomo G., Whitcomb D. C., Windsor J. A. Determinant – based classification of acute pancreatitis severity: an international multidisciplinary consultation. Ann. Surg. 2012; 256(6): 875–880.
  6. Rosenberg A., Steensma E. A., Napolitano L. M. Necrotizing pancreatitis: new definitions and a new era in surgical management. Surg Infect (Larchmt). 2015; 16(1): 1–13. DOI: 10.1089/sur.2014.123.
  7. Banks P.A., Bollen T. L., Dervenis C., Gooszen H. G., Johnson C. D., Sarr M. G., Tsiotos G. G., Vege S. S. Classification of acute pancreatitis –2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013; 62 (1): 102–111 DOI: 10.1136/gutjnl-2012–302779
  8. Ishikawa K., Idoguchi K., Tanaka H., Tohma Y., Ukai I., Watanabe H., Matsuoka T., Yokota J., Sugimoto T. Classification of acute pancreatitis based on retroperitoneal extension: Application of the concept of interfascial planes. Eur. J. Radiol. 2006; 60(3): 445–452.
  9. Dyuzheva T. G., Dzhus E. V., Shefer A. V., Akhaladze G. G., Chevokin A. Yu., Kotovskiy A. E., Platonova L. V., Shono N. I., Galperin E. I. Konfiguratsiya nekroza podzheludochnoy zhelezy i differentsirovannoye lecheniye ostrogo pankreatita. Annaly khirurgicheskoy gepatologii. 2013; 18. № 1: 92–102.
  10. Anishchenko V. V., Kim D. A., Baram G. I., Morozov V. V., Kovgan Yu.M., Kan B. V., Korkotyan A. G. Obosnovaniye neobkhodimosti rannego khirurgicheskogo lecheniya bolnykh s tyazhelym ostrym pankreatitom po sovokupnosti priznakov. Sibirskoye meditsinskoye obozreniye. 2017; 3: 43–49. DOI: 10.20333/2500136–2017–3–43–49.
  11. Dyuzheva T. G., Akhaladze G. G., Chevokin A. Yu., Shramko A. L. Differentsirovannyy podkhod k diagnostike i lecheniyu ostrykh zhidkostnykh skopleniy pri pankreonekroze. Ann. khir. gepatol. 2005;10(3):89–94.

Full text is published :
DEVELOPMENT OF PARAPANCREATITIS DEPENDING ON THE CONFIGURATION OF INJURY OF THE PANCREAS AT ACUTE NECROTIZING PANCREATITIS. Experimental and Clinical Gastroenterology Journal. 2018;151(03):71-77
Read & Download full text

1. “Perm State Medical University n. a. E. A. Vagner” of the Ministry of Healthcare of the Russia

Keywords: pancreatogenic ascites, pancreaticopleural fistula, pseudocysts of the mediastinum

Abstract:We reported nine cases of pancreatic ascites with the history of acute pancreatitis, disconnected pancreatic duct syndrome and three cases with mediastinal pancreatic pseudocysts and pancreaticopleural fistulas. Disconnected pancreatic duct syndrome was diagnosed through computer tomography in 87.5%. Our study supports the effectiveness of pancreatodigestive anastomosis for treatment disconnected pancreatic duct syndrome and mediastinal pancreatic pseudocysts, pancreaticopleural fistula, reducing the treatment time and improving the quality of life in the follow-up.

• References total 12 ⇓ :: .
  1. Jin S.G., Chen Z. Y., Yan L. N., Zeng Y. Delayed internal pancreatic fistula with pancreatic effusion postsplenectomy // World J Gastroenterol. - 2010. - Vol. 16, № 35 - P. 4494-4496.
  2. Irani S., Gluck M., Ross A. et al. Resolving external pancreatic fistulas in patients with disconnected pancreatic duct syndrome: using rendezvous techniques to avoid surgery // Gastrointest Endosc. - 2012. - Vol. 76, № 3 - P. 586-593.
  3. Wronski M., Slodkowski M., Cebulski W. et al. Optimizing management of pancreaticopleural fistulas // World J Gastroenterol. - 2011. - Vol. 17, № 42 - P. 4696-4703.
  4. Ninos A., Pierrakakis S. Role of diaphragm in pancreaticopleural fistula // World J Gastroenterol. - 2011. - Vol.17, № 32 - P. 3759-3760.
  5. Pai C.G., Suvarna D., Bhat G. Endoscopic treatment as first-line therapy for pancreatic ascites and pleural effusion // J Gasrtoenterol Hepatol. - 2009. - Vol. 24, № 7 - P. 1198-1202.
  6. Varadarajulu S., Noone T. C., Tutuian R. et al. Predictors of outcomes in pancreatic duct disruption managed by endoscopic transpapillary stent placement // Gastrointest Endosc. - 2005. - Vol. 61, № 4 - P. 568-575.
  7. Pelaez-Luna M., Vege S. S., Petersen B.T. et al. Disconnected pancreatic duct syndrome in severe acute pancreatitis: clinical and imaging characteristics and outcomes in a cohort of 31 cases // Gastrointest Endosc. - 2008. - Vol. 68, № 1 - P. 91-97.
  8. Tretiak S. I., Rashchinskiy S. M., Avdevich D. A. Pankreatogennyy astsit: analiz variantov khirurgicheskogo lecheniya // Novosti khirurgii. – 2009. – T. 17. № 3. – S. 17–22.
  9. Ali T., Srinivasan N., Le V. et al. Pancreaticopleural fistula // Pancreas. - 2009. - Vol. 38, № 1 - P. 26-31.
  10. Tay C.M., Chang S. K. Diagnosis and management of pancreaticopleural fistula // Singapore Med J. - 2013. - Vol. 54, № 4 - P. 190-194.
  11. Dabrowski K., Bialek A., Kukla M. et al. Mediastinal Pancreatic Pseudocysts // Clin Endosc. 2017. - Vol. 50, № 1 - P. 76-80.
  12. Wypych K., Serafin Z., Galazka P et al. Pancreaticopleural fistulas of different origin: Report of two cases and review of literature // Pol J Radiol. 2011. - Vol. 76, № 2 - Р. 56-60.

Full text is published :
INTERNAL PANCREATOGENIC FISTULAS: PANCREATOGENIC ASCITES AND PANCREATICOPLEURAL FISTULAS. Experimental and Clinical Gastroenterology Journal. 2018;151(03):78-82
Read & Download full text

1. Center for Strategic Planning Russian Ministry of Health
2. SM Kirov Military Medical Academy
3. AI Evdokimov Moscow State Medical-Stomatological University, Ministry of Health
4. Central State Medical Academy
5. Kraft LLC

Keywords: microbe/host cross talk, probiotic microorganisms, bioactive molecules, microbial structural components, metabolites, signaling molecules, simple and complex hybrid metabiotics

Abstract:The human symbiotic microbiota produces various bio-active molecules having chemical and functional similarity to dietary nutrients and /or endogenous compounds. Various factors and agents cause the imbalance of host/microbial dialogue. Currently for conservation and restoration of human microbial community various probiotics and prebiotics are used. Unfortunately, probiotic effects are often short term or absent or uncertain; traditional probiotics may also have non-desirable side effects in the application. For these reasons, the search for microbial molecule modifiers of host/microbe axis is emerging, especially with regard to personal medicine. These compounds have been named metabiotics (M). M are structural components of known probiotic microorganisms and/or their metabolites and/or signaling molecules that can restoring shortages and disruption of the balance of mitochondrial, microbial or cellular LMW substances with increased health effectiveness. They have some advantages (certain chemical structure, well dosed, safety, long shelf-life) in optimizing host gene expression, epigenetic, energetic, metabolic, immune, informational, regulatory, transport, neuro-hormonal and/or behavioral responses associated with the symbiotic microbiota. M can act as independent means or as enriching additives in functional foods. Simple microbial molecules can also be used in constructing hybrid M containing multiple metabolites and structural components separately or in combination with herbal compounds. Special attention should be paid to the design of M with specific targets in the host. Further investigations will clarify what natural microbial or artificial (semi-synthetic, synthetic, hybolite) pan- or selective M may affect host functions, biochemical and signal processes.

• References total 61 ⇓ :: .
  1. Ugolev A. M. Teoriya adekvatnogo pitaniya i Trofologiya- L. Nauka, 1991. - 372 s.
  2. Lederberg J. Infectious history. Science 2000; 288: 287-289.
  3. Tkachenko E. I. Paradigma disbioza v sovremennoy gastroenterologii. Rol’ mikrobioty v lechenii i profilaktike zabolevaniy v XXI veke. Eksperimental’naya i klinicheskaya gastroenterologiya. 2014; 105(5):4-7.
  4. Prescott S.L. History of medicine: Origin of the term microbiome and why it matterns. Human Microbiome Journal 2017; 4: 24-25.
  5. Shenderov B. A., Sinitsa A. V., Zakharchenko M. M. Metabiotiki: vchera, segodnya, zavtra. Sankt-Peterburg. OOO “Kraft”, 2017. - 80 s.
  6. Shenderov B. A. Modern condition and prospective host microecology investigations. Microb Ecol Health Dis 2007; 19: 145-149.
  7. Shenderov B. A. Mikrobnaya ekologiya cheloveka i yeye rol’ v podderzhanii zdorov’ya. METAFORMOZY. 2014; № 5:72-80.
  8. Shenderov B. A. Metabiotiki - novaya tekhnologiya profilaktiki zabolevaniy, svyazannykh s mikroekologicheskim disbalansom cheloveka. Vestnik vosstanovitel’noy meditsiny 2017; № 4: 40-49.
  9. Li J, Jia H, Cai X, Zhong H, Feng Q, Sunagawa S. et al. An Integrated catalog of reference genes in the human gut microbiome. Nat Biotechnol 2014; 32: 834-41.
  10. Gaci N., m Borrel G., Tottey W., O’Toole P/W, Brugere J-F. Archaea and the human gut: New beginning of an old story. World Journal of Gastroenterology 2014; 20(43): 16062-16078.
  11. Ardatskaya M. D., Bel’mer S. V., Dobritsa V. P., Zakharenko S. M., Lazebnik L. B., Minushkin O. N., Oreshko L. S, Sitkin S. I., Tkachenko E. I., Suvorov A. N., Khavkin A. I., Shenderov B. A. Disbioz (disbakterioz) kishechnika: sovremennoye sostoyaniye problemy, kompleksnaya diagnostika i lechebnaya korrektsiya. Eksperimental’naya i klinicheskaya gastroenterologiya 2015; 117 (5):13-50.
  12. Falony G., Joossens M., Viera-Silva S., Wang J., Darzi Y., Faust K., Kurilshikov A., Bonder M. J., Valles-Colomer M., Vandeputte D, Tito RY, Chaffron S., Rymenans L. et al. Population-level analysis of gut microbiome variation. Science 2016; 352 (6285): 560-564; DOI: 10.1126/science.aad3503.
  13. Zhernakova A, Kurilshikov A, Bonder M. J., Tigchelaar E.F, Schirmer M, Vatanen T. et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 2016; 352: 565-569.
  14. Proal A. D., Lindseth I.A, Marshall T. G. Microbe-Microbe and Host- Microbe Interactions Drive Microbiome Dysbiosis and Inflammatory Processes. Discovery Medicine 2017; 23(124): 51-60.
  15. Blum H.E. The human microbiome. Advance in Medical Sciences 2017;62:414-20.http://dx.doi.org/10.1016/j.advms.2017.04.005.
  16. Bik E. M., Ugalde J. A., Cousins J., Goddard A. D., Richman J., Apte Z. S. Microbial biotransformations in the human distal gut. British J Pharmacology 2017. DOI:10.1111/bph.14085.
  17. Sonnenburg JL, Backhed F. Diet-microbiota interactions as moderators of human metabolism. Nature 2016; 536: 56–64.
  18. Badretdinova L. M., Batregdinova R. R., Shenderov B. A. Sanatorno-kurortnoye lecheniye osteoartroza. Sovremennoye sostoyaniye i perspektivy. Yekaterinborg.: Izdatel’stvo AMB, 2012. - S. 99-117.
  19. Shenderov B. A. Probiotic (symbiotic) bacterial languages. Anaerobe 2011; 17: 490-495.
  20. Shenderov B.A. PROBIOTICS AND FUNCTIONAL FOODS, in Food Engineering, [Eds. UNESCO-EOLSS Joint Committee], in Encyclopedia of Life Support Systems (EOLSS), Developed under the Auspices of the UNESCO, Eolss Publishers, Oxford, UK, [http://www.eols.net]. 2011; 33p.
  21. Shenderov B.A, Midtvedt T. Epigenomic programing: a future way to health? Microbial ecology in Health & Disease 2014, 25: 24145 - http://dx.doi.org/10.3402/mehd.v25.24145.
  22. Stilling, R.M., Dinan, T.G., Cryan, J. F. Microbial genes, brain & behavior - epigenetic regulation of the gut-brain axis. Genes Brain Behav. 2014; 13 (1): 69-86. doi: 10.1111/gbb.12109.
  23. Galand, L. The gut microbiome and the brain. J Med Food. - 2014. - Dec. - Vol. 17 (12): 1261-72. - doi: 10.1089/jmf.2014.7000.
  24. Sampson, T.R., Mazmanitan, S. K. Control of brain development, function, and behavior by the microbiome. Cell Host Microbe 2015; 17 (5): 565-576. doi: 0.1016/j.chom.2015.04.011.
  25. Paul B., Barnes S., S. Demark-Wahnefried S, Morrow C, Salvador C, Skibola C, Tollrfboll OT. Influences of diet and the gut microbiome on epigenetic modulation in cancer and other diseases. Clinical Epigenetics 2015; 7.112. Doi:10.1186/s13148-015-0144-7.
  26. Oleskin A. V., El’-Registan G.I., Shenderov B. A. Mezhmikrobnyye khimicheskiye vzaimodeystviya i dialog mikrobiota-khozyain: rol’ neyromediatorov. Mikrobiologiya 2016; 85(1): 1-24.
  27. Oleskin A.V, Shenderov B.A, Rogovsky V.S. Role of Neurochemicals in the Interaction between the Microbiota and the Immune and the Nervous System of the Host Organism. Probiotics and Antimicrobial Proteins, February 2017. DOI: 10.1007/s12602-017-9262-1.
  28. Shenderov B.A. Metabiotics: novel idea or natural development of probiotic conception. Microb Ecol Health Dis 2013; 24: 20399-http:// dx.doi. org/10.3402/mehd.v24i0.20399.
  29. Sharma M, Shukla G. Metabiotics: One Step ahead of Probiotics; an Insight into Mechanisms Involved in Anticancerous Effect in Colorectal Cancer. Front Microbiol 7:1940. Doi: 10.3389/fmicb.2016.01940.
  30. Beloborodova N.V, Osipov G.A. Small molecules originating from microbes (SMOM) and their role in microbes-host relationship. Microb Ecol Health Dis 2000; 12:12e21.
  31. Nicolson G. L., Mattos de G.F., Settineri R., Costa C., Ellithorpe R., Rosenblatt S., Valle La J., Jimenez A., Ohta S. Clinical effects of hydrogen administration: from animal and human diseases to exercise medicine. Intern J Clin Medicine 2016; 7: 32-76. doi.org/10.4236/ijcm.2016.71005
  32. Lazebnik L. B., Konev Yu. V. Mikrobiota tolstoy kishki i sostavlyayushchiye metabolicheskogo sindroma // Eksperimental’naya i klinicheskaya gastroenterologiya. - 2014. - № 5. - S. 33-39.
  33. Ardatskaya M. D. Probiotiki, prebiotiki i metabiotiki v korrektsii mikroekologicheskikh narusheniy kishechnika. Meditsinskiy Sovet 2015; № 3: 94-9.
  34. Gibson G.R, Hutkins R, Sanders M.E, Prescott S.L, Reimer R.A, Salminen S.J. et al. The nternational scientific association for probiotics and prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nature Reviews Gastroenterology & Hepatology. Published online 14 Jun 2017. Doi: 10.1038/nrgast6ro. 2017.75.
  35. Nguen H-T, Truong D-H, Kouhonde S, Ly S, Razafindralambo H, Delvigne F. Biochemical engineering approaches for increasing viability and functionality of probiotic bacteria. Int J Mol Sci 2016 Jun 2; 17(6). pii: E867. Doi: 10.3390/ijms17060867.
  36. Katan A. Why the European Food Safety Authority was right to reject health claims or probiotics. Benefitial Microbes; 2012. 3(2): 85-89.
  37. Hill C, Guarner F, Reid G, Gibson G, Merenstein D, Pot B, Morelli L. et al. The International scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014; 11(8): 506-514. Doi: 10.1038/nrgastro.2014.66.
  38. Vakhitov T. Ya., Sitkin S. I. Kontseptsiya superorganizma v biologii i meditsine. Eksperimental’naya i klinicheskaya gastroenterologiya 2014; № 107 (7): 72-85.
  39. Vakhitov T. Yu., Petrov L. N., Bondarenko V. M. Kontseptsiya probioticheskogo preparata, soderzhashchego original’nyye mikrobnyye metabolity ZHMEI 2005; № 5: 108-114.
  40. Neish A.S. Microbes in gastrointestinal health and disease.Gastroenterology 2009; 136: 65-80.
  41. Sonnenburg J.L, Fischbach M.A. Community Health care: therapeutic opportunities in the human microbiome. Sci Transl Med 2011 Apr 13; 3(78): 78ps12. doi: 10.1126/scitranslmed. 3001626.
  42. Caselli M, Vaira G, Calo G, Papini F, Holton J, Vaira D. Structural bacterial molecules as potential candidates for an evolution of the classical concept of probiotics. Adv Nutr 2011; 2: 372-376.
  43. Thompson J. A., Oliveira R. A., Djukovic A., Ubeda C., Xavier K. B. Manipulation of the Quorum-Sensing Signal AI-2 Affects the Antibiotic-Treated Gut Microbiota. Cell Reports 2015; 10.
  44. Verbeke F, De Craemer S, Debunne N, Janssens Y, Wynendaele E, Van de Wiele C, De Spiegeleer B. Peptides as Quorum Sensing Molecules: Measurement Techniques and Obtained Levels In vitro and In vivo. Front. Neurosci. 2017;11:183. doi: 10.3389/fnins.2017.00183.
  45. Kamada N, Nunez G. Regulation of the immune system by the resident intestinal bacteria. Gastroenterology 2014; 146(6): 1477-88.
  46. Karczewski J, Poniedzialek B, Adamski Z, Rzymski P. The effects of the microbiota on the host immune system. Autoimmunity 2014. DOI: 10.3109/08916934.2014.938322.
  47. Blander J. M., Longman R. S., Iliev I. D., Sonnenberg G. F., Artis D. Regulation of inflammation by microbiota interactions with the host. Nature Immunology 2017; 18(6): 851-860.
  48. Lebeer S., Bron P. A., Marco M.L., Van Pijkeren J-P., O’Conell Motherway M., Hill C., Pot B., Roos S., Klaenhammer T. Identification of probiotic effector molecules: present state and future perspectives. Current Opinion in Biotechnology 2018; 49: 217-223.
  49. Wallace D.C. The epigenome and the mitochondrion: bioenergetics and the environment. Gen Dev 2010; 24:1571-1573.
  50. Wallace B. D., Redinbo M.T. The Human Microbiome is a Source of Therapeutic Drug Targets. Curr Opin Chem Biol 2013; 17(3):379-384. Doi:10.1016/j.cbpa.2013.04.011.
  51. Gao D., Gao Z., Zhu G. Antioxidant effects of Lactobacillus plantarum via activation of transcription factor Nrf2. Food Funct 2013; 4:982-989.
  52. Mishra V, Shah C, Mokashe N, Chavan R, Yadav H, Prajapati J. Probiotics as potential antioxidants: A systematic review. J. Agric Food Chem. 2015; 63: 3615-3626.
  53. Prosekov A., Dyshlyuk L., Milentyeva I, Sukhish S, Babich O, Ivanova S, Pavskyi V., Shishin M., Matskova L. Antioxidant, antimicrobial and antitumor activity of bacteria of the genus bifidobacterium, selected from the gastrointestinal tract of human. Integr Mol Med 2015; 2(5): 295-303.
  54. Jones R.M., Neish A. S. Redox signaling mediated by the gut microbiota. Free Radical Biology and Medicine 2017; 105: 41-47 http://dx.doi.org/10.1016/j.freeradbiomed.2016.10.495.
  55. Wang Y., Wu Y., Wang Y., Xu H, Mei X, Yu D, Wang Y, Li W. Antioxidant Properties of Probiotic Bacteria. Nutrients 2017; 9:521; doi: 10.3390/nu9050521.
  56. Shenderov B. A. Mikroekologicheskaya epigenetika stressa, zabolevaniy, zdorov’ya i dolgoletiya. Vestnik vosstanovitel’noy meditsiny 2016; № 1: 21-8.
  57. El Aidy S, Stilling R. M. Dinan T. G., Cryan J. T. Microbiome to Brain: Unravelling the multidirectional axes of communication. Microbial Endocrinology: Interkingdom signaling in infectious disease and health. M. Lyte (ed). Advances in Experimental Medicine and Biology. Chapter 15. Springer International Publishing AG 2016: 301-336. Doi: 10.1007/978-3-319-20215_15.
  58. Shenderov B.A (2016) The microbiota as an epigenetic control mechanism. Chapter 11. In: Nibali L, Henderson B (eds) The human microbiota and chronic disease: dysbiosis as a cause of human pathology. 1st ed, J. Wiley & Sons, pp.179-197.
  59. Legent G, Norris V. Hybolites: novel therapeutic toolsfor targeting hyperstructure in bacteria. Recent Pat on Antiinfect Drug Discov 2009; 4 (2): 90-5.
  60. Norris V, Verrier C, Feuilloley M. Hybolites Revisited. Recent Pat on Antiinfect Drug Discov 2016; 11 (1): 1-13. Send Orders for Reprints to reprints@ benyhamscience.ae.
  61. Kashyap P. C., Chia N., Nelson H., Segal E., Elinav E. Microbiome at the Frontier of Personalized Medicine. Mayo Clin Proc 2017; 92(12): 1855-1864. https://doi.org/10.1016/j.mayocp.2017.10.004.

Full text is published :
METABIOTICS - NOVEL TECHNOLOGY OF PROTECTIVE AND TREATMENT OF DISEASES ASSOCIATED WITH MICROECOLOGICAL IMBALANCE IN HUMAN BEING. Experimental and Clinical Gastroenterology Journal. 2018;151(03):83-92
Read & Download full text

1. Research Institute of Internal and Preventive Medicine - Branch of Federal State Budget Scientefic Institution The Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences
2. National Research State University

Keywords: pancreatic cancer, meta-analysis, prospective cohort studies, risk, coffee, tea

Abstract:Pancreatic cancer (PC) is one of the top 5 causes of mortality from cancer. The role of dietary factors in the etiology of PC is unclear. We reviewed some meta-analytical or pooled reports dealing with the association between coffee (C) and tea (T) consumption and PC risk. C components can have anticarcinogenic effect: meta-analysis by Dong (2011) confirmed, that pooled relative risk (RR) of PC in high C lovers comparing with non/lowest C drinkers was 0.68 (95% CI 0.51-0.84). But in the “US NIH-AARP Diet and Health Study” (2015) after adjustment for smoking, PC risk were not significant: never C drinkers compared with C drinkers≥6 cups per day (cpd) HR1.24 (0.93-1.65). In the European Prospective Investigation (2013) neither C, nor T were also associated with PC risk, but the previous Italian multicenter study (1995) was demonstrated, that ingestion of >3 cpd lead to significantly increased PC risk (odds ratio (OR) 2.53; 1.53-4.18). A meta-analysis by Zeng (2014) indicate, that green T consumption >2 cpd (OR0.95, 0.85-1.06) was not associated with PC risk. However, the subgroup analysis of different countries in meta-analysis by Chen (2014) showed a statistical decrease in PC risk by high T consumption in a Chinese population (Risk ratio=0.76, 0.59-0.98). Nevertheless meta-analysis, pooled and case-control studies are prone to some limitations (recall, selection bias) - different dietary patterns, adjustment for different confounders, etc. Further research is needed to clarify the biological mechanisms in the possible inverse relationship between C, T intake and PC risk.

• References total 29 ⇓ :: .
  1. Ferlay J., Soerjomataram I., Ervik M., et al. GLOBOCAN2012 v1.1, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet] Lyon, France: International Agency for Research on Cancer; 2014.
  2. Michaud D. S. Role of bacterial infections in pancreatic cancer. //Carcinogenesis. 2013; 34(10): 2193-2197.
  3. Jemal A., Bray F., Center M., et al. Global cancer statistics. // Cancer J. Clin. 2011;61:69-90.
  4. Dong J., Zou J., Yu X. Coffee drinking and pancreatic cancer risk: a meta-analysis of cohort studies. //World J. Gastroenterol. 2011;17(9):1204-1210.
  5. Bode A. M., Dong Z. The enigmatic effects of caffeine in cell cycle and cancer. //Cancer Lett. 2007; 247(1):26-39.
  6. Guertin K. A., Freedman N. D., Loftfield E., et al. A prospective study of coffee intake and pancreatic cancer: results from the NIH-AARP Diet and Health Study. //Br. J. Cancer. 2015;113(7):1081-1085.
  7. Bhoo-Pathy N., Uiterwaal C. S., Dik V. K., et al. Intake of coffee, decaffeinated coffee, or tea does not affect risk for pancreatic cancer: results from the European Prospective Investigation into Nutrition and Cancer Study. //Clin. Gastroenterol. Hepatol. 2013;11(11):1486-1492.
  8. Bidel S., Hu G., Jousilahti P., et al. Coffee consumption and risk of gastric and pancreatic cancer - a prospective cohort study. //Int. J. Cancer. 2013;132(7): 1651-1659.
  9. Turati F., Galeone C., Edefonti V., et al. A meta-analysis of coffee consumption and pancreatic cancer. //Ann Oncol. 2012;23(2):311-318.
  10. Gullo L., Pezzilli R., Morselli-Labate A.M., et al. Coffee and cancer of the pancreas: an Italian multicenter study. // Pancreas. 1995;11(3):223-229.
  11. Nie K., Xing Z, Huang W, et al. Coffee intake and risk of pancreatic cancer: an updated meta-analysis of prospective studies. //Minerva Med. 2016;107(4): 270-278.
  12. Ran H. Q., Wang J. Z., Sun C. Q. Coffee Consumption and Pancreatic Cancer Risk: An Update Meta-analysis of Cohort Studies. //Pak J. Med. Sci. 2016;32(1): 253-259.
  13. Nishi M., Ohba S., Hirata K. et al. Dose-response relationship between coffee and the risk of pancreas cancer. // Jpn. J. Clin. Oncol. 1996;26(1):42-48.
  14. Wang A., Wang S., Zhu C., et al. Coffee and cancer risk: A meta-analysis of prospective observational studies. //Sci. Rep. 2016; 6, 33711.
  15. Feng R., Lu Y., Bowman L. L., et al. Inhibition of activator protein-1, NF-kappaB, and MAPKs and induction of phase 2 detoxifying enzyme activity by chlorogenic acid. // J. Biol. Chem. 2005; 280(30):27888-27895.
  16. Dong S., Kong J., Kong J., et al. Low Concentration of Caffeine Inhibits the Progression of the Hepatocellular Carcinoma via Akt Signaling Pathway. //Anticancer Agents Med. Chem. 2015; 15(4):484-492.
  17. Higdon J. V., Frei B. Coffee and health: a review of recent human research. //Crit. Rev. Food Sci. Nutr. 2006; 46(2):101-23.
  18. Li D., Jiao L. Molecular epidemiology of pancreatic cancer. //Int. J. Gastrointest. Cancer. 2003;33(1):3-14.
  19. Porta M., Malats N., Guarner L., et al. Association between coffee drinking and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group. // J. Epidemiol. Community Health. 1999; 53(11): 702-709.
  20. Genkinger J. M., Li R., Spiegelman D., et al. Coffee, tea, and sugar-sweetened carbonated soft drink intake and pancreatic cancer risk: a pooled analysis of 14 cohort studies. //Cancer Epidemiol. Biomarkers Prev. 2012;21(2):305-318.
  21. Appari M., Babu K. R., Kaczorowski A. et al. Sulforaphane, quercetin and catechins complement each other in elimination of advanced pancreatic cancer by miR-let-7 induction and K-ras inhibition. //Int. J. Oncol. 2014;45(4):1391-400.
  22. Zhang Y. F., Xu Q., Lu J., et al. Tea consumption and the incidence of cancer: a systematic review and meta-analysis of prospective observational studies. //Eur. J. Cancer Prev. 2015;24(4):353-362.
  23. Zeng J. L., Li Z. H., Wang Z. C., Zhang H. L. Green tea consumption and risk of pancreatic cancer: a meta-analysis. // Nutrients. 2014;6(11):4640-4650.
  24. Chang B., Sang L., Wang Y., et al. Consumption of tea and risk for pancreatic cancer: a meta-analysis of published epidemiological studies. //Nutr. Cancer. 2014;66(7):1109-1123.
  25. Chen K., Zhang Q., Peng M., et al. Relationship between tea consumption and pancreatic cancer risk: a meta-analysis based on prospective cohort studies and case-control studies. // Eur. J. Cancer Prev. 2014;23(5):353-360.
  26. Shibata A., Mack T. M., Paganini-Hill A., et al. A prospective study of pancreatic cancer in the elderly. // Int. J. Cancer. 1994;58:46-49.
  27. Zatonski W., Boyle P., Przewozniak K., Maisonneuve P. Cigarette smoking, alcohol, tea and coffee consumption and pancreas cancer risk: a case-control study from Opole, Poland. //Int. J. Cancer. 1993;53:601-607.
  28. Jansen R. J., Tan X-L., Petersen G. M. Gene-by-Environment Interactions in Pancreatic Cancer: Implications for Prevention. //Yale J. Biol. Med. 2015; 88(2): 115-126.
  29. Bracken M. B., Triche E., Grosso L., et al. Heterogeneity in assessing self-reports of caffeine exposure: implications for studies of health effects. //Epidemiology. 2002; 13(2):165-171.

Full text is published :
PANCREATIC CANCER RISK FACTORS: A SUMMARY REVIEW OF META-ANALYTICAL AND PROSPECTIVE COHORT STUDIES PART 1. COFFEE AND TEA CONSUMPTION. Experimental and Clinical Gastroenterology Journal. 2018;151(03):93-96
Read & Download full text

1. National Research Ogarev Mordovia State University

Keywords: pancreatitis, diagnostics, treatment, pregnancy

Abstract:The article gives up-to-date information about the most frequent, clinical pictures, diagnostics methods, differential diagnostics and treatment pancreatitis during pregnancy.

• References total 41 ⇓ :: .
  1. Pregravidarnaya podgotovka: klinicheskiy protokol /Avt.-razrab. V. E. Radzinskiy i dr. M., 2016. – 80 s.
  2. Scott L. D. Gastrointestinal Disease in Pregnancy. In W. J. Creasy, R. Resnik (eds.), Maternal-Fetal Medicine, Principles and Practice (3rd ed.). Philadelphia: Saunders, 2004.
  3. Jennifer J. Eddy, Mark D. Gideonsen, Jonathan Y. Song, William A. Grobman, Peggy O’Halloran Pancreatitis in pregnancy //Obstetrics and Gynecology. - 2008. - V.112(5). - P. 1075-1081.
  4. Hernandez A., Petrov M. S., Brooks D. C. et al. Acute pancreatitis and pregnancy: a 10 year single center experience //J Gastrointestinal Surg. - 2007. - V.11.-Р.1623-1627.
  5. Mayev I. V., Kazyulin A. N., Dicheva D. T. i dr. Khronicheskiy pankreatit. Moskva. VUMNTs. 2003.
  6. Samsonov A. A. Sovremennaya farmakoterapiya khronicheskogo pankreatita //Rossiyskiye apteki. – 2007.-№ 3.S.30–32.
  7. Nair R. J., Lawler L., Miller M. R. Chronic Pancreatitis // Am Fam Physician. - 2007. - V.76 (11).-Р.1679-1688.
  8. Banks P. A., Freeman M. L. Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines in acute pancreatitis //Am. J. Gastroenterol. - 2006. - V.101.-Р.2379-2400.
  9. Tang S. J., Mayo M. L., Rodriges-Frias E., et al. Safety and utility of ERCP during pregnancy //Gastrointest. Endosc. - 2009. - V.69.-Р.453-461.
  10. Swisher S. G., Hunt K. K., Schmit P. J., et al. Management of pancreatitis complicating pregnancy //Am Surg. - 2006. - V.60.-Р.759-762.
  11. Ramin K. D., Ramin S. M., Richey S. D., Cunningham F. G. Acute pancreatitis in pregnancy //Am J Obstet Gynecol. - 2005. - V.173.-Р.187-191.
  12. Pitchumoni C. S., Yegneswaran B. Acute pancreatitis in pregnancy //World Journal of Gastroenterology. - 2009.-V.15, № 45.-Р.5641-5646.
  13. Poddar S., Pitchumoni C. Pregnancy associated pancreatitis revisited //Clinics and Research in Hepatology and Gastroenterology.-2013. - V.37.-№ 2.-Р.177-181.
  14. Zhang D.-L., Huang Y., Yan L. et al. Thirty-eight cases of acute pancreatitis in pregnancy: a 6-year single center retrospective analysis //Journal of Huazhong University of Science and Technology.2013. - V.33.-№ 3.-Р.361-367.
  15. Eddy J. J., Gideonsen M. D., Song J. Y., et al. Pancreatitis in Pregnancy //Obstetrics & Gynecology. - 2008. V.112 (5).-Р.1075-1081.
  16. Block P., Kelly T. R. Management of gallstone pancreatitis during pregnancy and the postpartum period //Surg Gynecol Obstet. - 2004. - V.168.-Р.426-428.
  17. Shou-Jiang Tang, E. Rodriguez, Sundeep Singh et al. Острый панкреатит у беременных //Клиническая гастроэнтерология и гепатология. Русское издание. - 2011. Т. 4(4).-Р.207-212.
  18. Bahiyah A., Thanikasalam K.P, Lim H. C., Ray J. R. // Severe Acute Pancreatitis in Pregnancy. Case Reports in Obstetrics and Gynecology.-2015, Article ID239068, 4 pages http:dx.doi.org/10.1155/2015/239068
  19. Ramin K. D., Ramsey P. S. Disease of the gallbladder and pancreas in pregnancy //Obstet Gynecol Clin North Am. -2001. - V.28.-Р.571-580.
  20. Styazhkina S. N., Sitnikov V. A., Ledneva A. V. i dr. Ostryy destruktivnyy pankreatit v III trimestre beremennosti i v poslerodovom periode //Meditsinskiy almanakh. – 2010.-№ 1.-S.96–98.
  21. Nies B. M., Dreiss R. J. Hyperlipidemic pancreatitis: a case report and review of the literature //Am J Perinatol. - 2008. - V.7.-Р.166-169.
  22. Ohmoto K., Neishi Y., Miyake I., Yamamoto S. Severe acute pancreatitis associated with hyperlipidemia: report of two cases and review of the literature in Japan // Hepatogastroenterology. - 2006. - V.46.-Р.2986-2990.
  23. Boakye M. K., Macfoy D., Rice C. Alcoholic pancreatitis in pregnancy //J Obstet Gynaecol. -2006. - V.26.-Р.814.
  24. Abu Musa A. A., Usta I. M., Rechdan J. B., Nassar A. H. Recurrent hypertriglyceridemia-induced pancreatitis in pregnancy: a management dilemma //Pancreas. - 2006. - V.32.-Р.227-228.
  25. Schnatz P. F., Curry S. L. Primary hyperparathyroidism in pregnancy: evidence-based management //Obstet Gynecol Surv. - 2002. - V.57.-Р.365-376.
  26. Murli Manohar, Alok K. Verma, Sathisha Upparahalli Venkateshaiah Hemant Goyal, Anil Mishra Food-Induced Acute Pancreatitis //Digestive Diseases and Sciences. - 2017. - V.62(12).-Р.3287-3297.
  27. Yadav D., Pitchumoni C. S. Issues in hyperlipidemic pancreatitis //J Clin Gastroenterol. - 2003. - V.36.-Р.54-62.
  28. E. P. Papadakis, M. Sarigianni, D. P. Mikhailidis, A. Mamopoulos, V. Karagiannis Acute pancreatitis in pregnancy: an overview //European Journal of Obstetrics Gynecology and Reproductive Biology.-2011. - V.159(2).-Р.261-266.
  29. Pandey R., Jacob A., Brooks H. Acute pancreatitis in pregnancy: review of three cases and anaesthetic management // International Journal of Obstetric Anesthesia.-2012. - V.21(4).-Р.360-363.
  30. Banks P. A., Bollen T. L., Dervenis C. et al. Classification of acute pancreatitis-2012: revision of the Atlanta classification and definitions by international consensus. - Gut.-2013. - V.62(1).-Р.102-111
  31. Standarty «Diagnostika i lekarstvennaya terapiya khronicheskogo pankreatita». prinyatyye na IX syezde NOGR4 marta 2009 g. /Podgot. k publ. Lazebnik L. B. Vasilyev Yu.V. // Eksperimental’naya i klinicheskaya gastroenterologiya.-2009.-№ 3.-S.137–149.
  32. Eremina E. Yu., Masharova A. A. Zabolevaniya organov pishchevaritelnoy sistemy u beremennykh. Saransk. – 2009.-201 s.
  33. Sun Y., Fan C., Wang S. Clinical analysis of 16 patients with acute pancreatitis in the third trimester of pregnancy // International Journal of Clinical and Experimental Pathology.-2013. - V.6(8).-Р.1696-1701.
  34. Shoaib Gangat A. R., Muhammad A., Saher F., Ameer A., Iqbal Ahmed M. Frequency of acute pancreatitis in pregnancy and it’s outcome //Pakistan Journal of Surgery.-2009. - V.25(2).-Р.69-71.
  35. Slovokhodov E. K. Ostryy pankreatit pri beremennosti //Novyy khirurgicheskiy arkhiv. – 2002.-№ 5 (1). – S.27–31.
  36. Tang S.-J., Rodriguez-Frias E., Singh S. et al. Acute pancreatitis during pregnancy //Clinical Gastroenterology and Hepatology.-2010.-V.8(1).-Р.85-90.
  37. Štimac T., Štimac D. Acute Pancreatitis During Pregnancy //European journal of gastroenterology & hepatology.-2011. - V.23(10).-Р.839-844.
  38. Mayev I. V. Khronicheskiy pankreatit (Algoritm diagnostiki i lechebnoy taktiki). – M., 2006.-104 s.
  39. Igbinosa O., Poddar S., Pitchumoni C. Pregnancy associated pancreatitis revisited //Clinics and Research in Hepatology and Gastroenterology.-2013. - V.37(2).-Р.177-181
  40. Jafri N. S., Mahid S. S., Idstein S. R., Hornung C. A., Galandiuk S. Antibiotic prophylaxis is not protective in severe acute pancreatitis: a systematic review and meta-analysis //The American Journal of Surgery.-2009.-V.197(6).-Р.806-813
  41. Testoni P. A. et al. Idiopathic recurrent pancreatitis: Long-term results after ERCP, endoscopic sphincterotomy, or ursodeoxycholic acid treatment //Am. J. Gastroenterol. – 2000. – V.95.-Р.1702–1707.

Full text is published :
PANCREATITIS IN PREGNANCY. Experimental and Clinical Gastroenterology Journal. 2018;151(03):97-104
Read & Download full text

1. Saint-Petersburg University
2. Ott Research Institute of Obstetrics, Gynecology and Reproductology

Keywords: liver, pregnancy, holestatichepatosis of pregnants, acute fatty hepatosis of pregnants, HELLP-syndrome, unrestrained vomiting of pregnants

Abstract:Тhis article demonstrates review of relevant clinical recommendations about diagnostics, care and treatment of liver diseases at pregnants. Recommendations about an algorithm of diagnostic search of liver pathology are provided in the first message during pregnancy, with assessment of indicators changes at biochemical blood serum research of “the hepatic panel”, opportunities and indications for methods of visualization and endoscopy. The liver diseases associated with pregnancy from positions of the available recommendations are considered and also results of own observations are given.

• References total 18 ⇓ :: .
  1. Tram T. T., Ahn J., Reau N. S. ACG Clinical Guideline: Liver Disease and Pregnancy. Am J Gastroenterol., 2016, vol. 111, pp. 176-194
  2. Lelevich. S. V. Kliniko-laboratornyye osobennosti perioda beremennosti: uchebno-metodicheskoye posobiye dlya studentov lechebnogo. pediatricheskogo fakultetov i vrachey / S. V. Lelevich. – Grodno: GrGMU. 2010. – 52 s.
  3. Palgova. L. K. Bolezni pecheni. svyazannyye s beremennostyu: Klinicheskiye rekomendatsii obshchestva akusherov – ginekologov Sankt-Peterburga i SZFO i Sankt-Peterburgskogo obshchestva gastroenterologov. gepatologov i diyetologov / L. K. Palgova. E. V. Mozgovaya. N. V. Zhestkova. E. K. Aylamazyana «red» – SPb.: Eko-Vektor. 2017. – 47 s.
  4. Hay J. E. Liver disease in pregnancy. Hepatology, 2008, vol. 47, pp. 1067-1076.
  5. Bolin M., Akerud H., Cnattingius S. [et аl.] Hyperemesis gravidarum and risks of placental dysfunction disorders: a population-based cohort study. BJOG, 2013, vol. 120, no. 5, pp. 541-547.
  6. Ayyavoo A., Derraik J. G., Hofman P. L. [et аl.] Severe hyperemesis gravidarum is associated with reduced insulin sensitivity in the offspring in childhood. J ClinEndocrinolMetab, 2013, vol. 98, no. 8, pp. 3263-3268.
  7. Einarson T.R., Piwko C., Koren G. Quantifying the global rates of nausea and vomiting of pregnancy: a meta analysis. J Popul TherClinPharmacol, 2013, vol. 20, pp. e171-183.
  8. Conchillo J. M., Pijnenborg J. M., Peeters P. [et al.] Liver enzyme elevation induced by hyperemesis gravidarum: aetiology, diagnosis and treatment. Neth J Med, 2002, vol. 60, pp. 374-378.
  9. Matthews A., Haas D. M., O’Mathúna D. P., Dowswell T. Interventions for nausea and vomiting in early pregnancy. Cochrane Database Syst Rev, 2014, 3: CD007575.
  10. Aylamazyan. V. I. Natsionalnoye rukovodstvo “Akusherstvo”: uchebnoye posobiye /E.K. Aylamazyan «red». V. I. Kulakova. V. E. Radzinskogo. G. M. Savelyevoy – M.: GEOTAR-Media. 2009. – 1200 c.
  11. Filippova. G. G. Psikhologiya materinstva: uchebnoye posobiye /G.G. Filippova – M.: Izd-vo Instituta Psikhoterapii. 2002. – 240 c.
  12. Dobryakov I. V. Trevozhnyy tip psikhologicheskogo komponenta gestatsionnoy dominanty //Psikhologiya i psikhoterapiya. Trevoga i strakh: edinstvo i mnogoobraziye vzglyadov (Materialy V ezhegodnoy Vserossiyskoy nauchno-prakticheskoy konferentsii (8–9.02. 2003goda). – SPb.: Izd-vo SPbGU. 2003. – c. 52–56.
  13. Marschall H. U., Wikstrom-Shemer E., Ludvigsson J. F.[et al.] Intrahepatic cholestasis of pregnancy and associated hepatobiliary disease: a population - based cohort study. Hepatology, 2013, vol. 58, pp.1385-1391.
  14. Elinav E., Ben-Dov I. Z., Shapira Y. [et al.] Acute hepatitis A infection in pregnancy is associated with high rates of gestational complications and preterm labor. Gastroenterology, 2006, vol. 130, pp. 1129-1134.
  15. Ibdah J. A., Bennett M. J., Rinaldo P. [et al.] A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med, 1999, vol. 340, pp. 1723.
  16. Kuzmin V. N. Serobyan A. G. Ostryy zhirovoy gepatoz beremennykh v praktike akushera-ginekologa. Lechashchiy vrach. 2003. № 5. s. 12–19.
  17. Yushchuk N. D. Kuzmin V. N. Malyshev N. A. [i dr.] Ostryy zhirovoy gepatoz v infektsionnoy i akusherskoy praktike. Klinicheskaya meditsina. 2002. № 10. c. 51–56.
  18. Martin J. N. Jr., Owens M. Y., Keiser S. D.[et al.] Standardized Mississippi Protocol treatment of 190 patients with HELLP syndrome: slowing disease progression and preventing new major maternal morbidity. Hypertens Pregnancy, 2012, vol. 31, pp. 79-90

Full text is published :
DISEASES OF THE LIVER AND PREGNANCY. ANALYSIS OF ACTUAL CLINICAL GUIDELINES AND OWN EXPIRIENCE. PART ONE. LIVER DISEASES АSSOCIATED WITH PREGNANCY. Experimental and Clinical Gastroenterology Journal. 2018;151(03):105-114
Read & Download full text

1. V. I. Vernadsky Crimean Federal University
2. Kazan Federal University
3. Kazan State Medical University

Keywords:history of anatomy, ductus pancreaticus, Johann Georg Wirsung, Jean Riolan-junior

Abstract:An article provides author’s translation from Latin of letters between Johann Georg Wirsung (1589-1643) and his teacher Jean Riolan-junior (1580-1657) concerning anatomy and function of ductus pancreaticus, promulgated by Riolan in own work «Opuscula anatomica nova» (1649). Produced correspondence shows that both researches were very far from correct understanding of function of entity discovered by Wirsung. First, who suggested a role of pancreatic duct fluid in digestion, was famous Dutch physician and scientist Franciscus Sylvius (1614-1672), assumed this idea in 1659.

• References total 4 ⇓ :: .
  1. Kutya S. A. Zhizn i smert Ioganna Georga Virsunga (k 370-letiyu so dnya otkrytiya protoka podzheludochnoy zhelezy) // Klіnіchna anatomіya ta operativna khіrurgіya. – 2012. – № 3. – S. 119–121.
  2. Howard J. M., Hess W., Traverso W. Johann Georg Wirsung (1589-1643) and the pancreatic duct: the prosector of Padua, Italy // J. Am. Coll. Surg. - 1998. - Vol. 187, № 2. - P. 201-211. DOI: 10.1016/S1072-7515(98)00136-7
  3. Riolan J. Opuscula anatomica nova. Londini: Typis Milonis Flesher, 1649. - 536p
  4. Kutia S. A., Sataieva T. P., Kriventsov M. A., Polishchuk E. A. Pancreas: history in a timeline // Experimental and Clinical Gastroenterology. 2017;141(5): 74-78

Full text is published :
ON THE HISTORY OF DISCOVERY AND DESCRIPTION OF ANATOMY AND FUNCTION OF DUCTUS PANCREATICUS. Experimental and Clinical Gastroenterology Journal. 2018;151(03):115-118
Read & Download full text

1. «Perm State Medical University n. a. E. A. Vagner» of the Ministry of Healthcare of the Russia

Abstract:The on-site Plenary Session of the Gastroenterological Scientific Society of Russia was dedicated to two issues - medicinal lesions of the liver and features of the pathology of the digestive system in women. The meeting was organised by the Gastroenterological Scientific Society of Russia, the Ministry of Health of the Perm Region, the Perm State Medical University n.a. Acad. E. A. Wagner of the Ministry of Health of the Russian Federation and the Association of Therapeutic Physicians of the Perm Territory. The forum was attended by over 200 specialists from Perm and the Perm Territory.

Full text is published :
PLENUM OF THE GASTROENTEROLOGICAL SCIENTIFIC SOCIETY OF RUSSIA (PERM, MARCH 3, 2018, GSSR) “MEDICINAL LESIONS OF THE LIVER. FEATURES OF THE PATHOLOGY OF THE DIGESTIVE SYSTEM IN WOMEN”. Experimental and Clinical Gastroenterology Journal. 2018;151(03):119-120
Read & Download full text